Published in final edited form as:

Biochem Pharmacol. 2008 January 1; 75(1): 112–133.

Homers regulate drug-induced neuroplasticity: Implications for addiction

Karen K. Szumlinski, Alexis W. Ary, and Kevin D. Lominac

Behavioral and Neural Genetics Laboratory, Department of Psychology and the Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, CA, 93106-9660

Abstract

Drug addiction is a chronic, relapsing disorder, characterized by an uncontrollable motivation to seek and use drugs. Converging clinical and preclinical observations implicate pathologies within the corticolimbic glutamate system in the genetic predisposition to, and the development of, an addicted phenotype. Such observations pose cellular factors regulating glutamate transmission as likely molecular candidates in the etiology of addiction. Members of the Homer family of proteins regulate signal transduction through, and the trafficking of, glutamate receptors, as well as maintain and regulate extracellular glutamate levels in corticolimbic brain regions. This review summarizes the existing data implicating the Homer family of protein in acute behavioral and neurochemical sensitivity to drugs of abuse, the development of drug-induced neuroplasticity, as well as other behavioral and cognitive pathologies associated with an addicted state.

Introduction

The hypothesis that abnormal corticolimbic glutamate transmission contributes to the pathophysiology of addiction emerged from decades of neurological, brain imaging, pharmacological, genetic and biochemical research in affected individuals, as well as behavioral, molecular, electrophysiological and neurochemical data derived from preclinical animal models of addiction [c.f. 1–4]. The vast number of clinical neuroimaging studies conducted on addicted individuals reveal striking abnormalities in prefrontal cortex (PFC) activity, relative to control subjects, that include reduced basal metabolic activity, reduced regional activation upon presentation of cues associated with non-drug primary reinforcers and enhanced metabolic activity upon presentation of drug-associated cues [e.g., 5–9]. Importantly, these abnormalities in PFC activity appear to be common across various drug addictions (incl. cocaine, methamphetamine, alcohol, cannabis, heroin and dissociative anesthetics), as well as across such non-drug addictions as gambling, and correlate with self-reports of “craving” and impairments in self-control in addicted individuals [6,9–17].

Preclinical efforts to understand the cellular basis for drug addiction-related abnormalities in mesocorticolimbic glutamate function have employed a variety of experimental approaches to examine the psychobiological consequences of repeated, non-contingent drug administration [18–22] and many of these findings have been confirmed in various animal models of drug-taking or drug-seeking [c.f., 23–27]. The integrity of the corticoaccumbens glutamate pathway is required for expressing many drug-induced changes in behavior, including the sensitization

To whom correspondence should be addressed: Karen K. Szumlinski, Ph.D., Department of Psychology, University of California Santa Barbara, Santa Barbara, CA, USA 93106-9660.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

of a drug's psychomotor-activating effects [e.g., 28–37], the development of tolerance to a drug's psychomotor-inhibiting effects [e.g., 38,39], drug-conditioned place-preference [e.g., 36,38,40–43], the maintenance of drug self-administration [e.g., 44–46] and the reinstatement of drug-seeking [47–56]. Further, *in vivo* microdialysis studies have revealed pronounced effects of either acute or repeated drug-induced changes in NAC or PFC extracellular levels of glutamate by a number of drugs of abuse, including: cocaine [e.g., 31,35,37,47,53,57,58], amphetamines [e.g., 20,59,60–62, but see 63], alcohol [38,39,64], nicotine [65–68] and opiates [69,70], implicating drug-induced changes in presynaptic aspects of corticoaccumbens glutamate transmission in mediating the changes in behavior produced by drugs of abuse. Finally, postsynaptic aspects of corticoaccumbens glutamatergic signaling regulate either the self-administration of various drugs of abuse, or the potential to relapse to drug-seeking, in both humans and laboratory animals. Acamprosate, a mixed antagonist at the NMDA ionotropic glutamate receptor (iGluR) and the mGluR5 subtype of the Group1 metabotropic glutamate receptor (mGluR) [71,72], is clinically effective at treating alcoholism [73,74] and may prove to be effective for treating psychomotor stimulant and opiate addiction [75,76]. Moreover, direct pharmacological manipulation of glutamate receptors within the PFC or the NAC result in reduced behavioral responsiveness to various drugs of abuse, including cocaine [48,50,53,77–79; but see 80], alcohol [e.g., 44,81,82], amphetamines [e.g., 83–89] and opiates [90–92, but see 79], and systemic administration of antagonists of glutamate receptors blocks several aspects of nicotine reward in laboratory animals [e.g., 93–100, but see 101]. Taken together, these data pose cellular factors regulating pre- and postsynaptic aspects of corticoaccumbens glutamatergic transmission as likely molecular candidates contributing to an addicted phenotype. This review summarizes the evidence supporting a key role for the Homer family of proteins in corticoaccumbens glutamate transmission as it relates to the psychomotor-activating and rewarding properties of drugs of abuse.

Molecular aspects of Homer proteins

The Homer family of proteins is the product of three independent mammalian genes (*Homer1–3*), one *Xenopus* gene and one *Drosophila* gene [102–105]. In humans, Homer1, Homer2 and Homer3 are localized to chromosomes 5, 15 and 19, respectively [105] and Homer transcripts have been identified in many different tissues including: brain, retina, liver, kidney, spleen, testis, thymus, placenta, intestine, as well as cardiac, skeletal and smooth muscle [105–107]. First described in the late 1990's, the original family of Homer proteins consisted of Homer1a/b/c, Homer2a/b and 3 [102–105]. Since that time, 21 *Homer* mRNAs have been isolated from rat, mouse and human brain, however the proteins for some of these mRNAs have yet to be detected in mammalian brain tissue [107–109]. The mammalian genes encoding the Homer family of proteins have open reading frames that spread over 10 exons and can give rise to both constitutively expressed, as well as immediate early gene (IEG) products [102, 104,110,111]. Exon 1 encodes the 5' untranslated region (UTR) and contains the translational initiation codon ATG. Up-stream of the initiation codon lie several multiple start site elements downstream motifs [MED-1; GCTCC(G/C)] indicating that *Homer* genes may contain multiple transcription initiation sites. Also located up-stream of the putative start site is a number of transcription factor binding sites, including: Sp1 (specific promoter 1), AP1 (activator protein 1), GATA, octamer recognition site, E box (enhancer box element) and CRE (cyclic adenosine monophosphate response element) [e.g., 110]. Thus, the transcription of *Homer* genes can be influenced by activation of immediate early genes and the mitogen-activated protein kinase (MAPK) cascade, as well as by CRE binding protein (CREB), all of which are highly implicated in the neurobiology of addiction [c.f.,112–118].

With the exception of the recently characterized Homer1g [111], exons 2–5 encode an Enabled/vasodilator-stimulated phosphoprotein (Vasp) homology 1 (EVH1) domain [119,120], which is similar in sequence to other Ena/Vasp proteins that regulate cytoskeleton dynamics [121].

The EVH1 domain exhibits a RxxxxxGLGF sequence that is common to most post-synaptic density 95(PSD-95)/Drosophila discs large tumor suppressor gene (Dlg)/Zona occludens-1 (ZO-1) (PDZ) domains that mediate protein-protein interactions and are involved in ion channel and receptor targeting to the plasma membrane [c.f., 122]. The EVH1 domain exhibits a high degree of similarity across Homer isoforms and is essential for Homer interactions with a proline-rich sequence (PPSPF) displayed by proteins regulating drug-induced alterations in neuronal morphology, synaptic architecture, and glutamate receptor signaling/intracellular calcium dynamics. Of particular relevance to drug-induced neuroplasticity [e.g., 20,73,74, 78–82,89–100,123–130], these proteins include the mGluR1a and mGluR5 subtypes of Group 1 metabotropic glutamate receptors (mGluRs) [34,102,104,107,131–137], the NMDA glutamate receptor scaffolding protein Shank [38,132,138,139], the inositol-1,4,5-triphosphate (IP3) receptor, a down-stream mediator of Group1 mGluR signaling [133,140–144], F-actin [145–151], and phosphoinositide 3 kinase (PI3K) enhancer-long (PIKE-L) [152] (see Fig 1).

In contrast to the high (~80%) sequence homology within exons 2–5 of the 3 Homer genes, exons 6–10 exhibit low homology (~20–30%) [105,107]. Exons 6–10 encode the carboxy-tail of the majority of Homer proteins that consists of a coiled-coil (CC) domain, 2 leucine zipper motifs and encode also the 3' UTR [104,105,107]. Homer proteins multimerize through CC/leucine zipper motif interactions [104,105,107,133,143,144] and a recent elucidation of the quaternary structure of Homers indicate that these proteins form tetramers with each monomer oriented in parallel [143]. The tetrameric structure of Homer oligomers confers slower turn-over rates and greater efficiency of localization to dendritic spines [143].

Alternative transcript splicing in regions downstream from exon 5 has been reported for all 3 Homer genes and can result in premature termination of transcription prior to the sequences encoding the CC and leucine zipper motifs [102,105,107,110]. This premature termination of transcription results in truncated or “short” Homer isoforms that lack the motifs necessary to multimerize. In neurons, the most characterized and thoroughly investigated is the bimodal expression of Homer1 constitutive (Homer1b-g) and IEG (Homer1a and Ania-3) products [c.f., 145–149]. Within the *Homer1* gene lies transcriptional stop codons in intron 5 and sequence comparison between rat cDNA for *Homer1a* [102,150] and the mouse Homer1 gene established that *Homer1a* mRNA terminates ~4.4 kb into intron 5 [110]. The intronic sequence extends exon 5 by 33 bases (11 codons), followed by a translational stop codon, and a ~4.4 kb 3' UTR, colinear with the 5' portion of intron 5. Ania-3, the other known IEG Homer1 isoform [108], is generated by alternative transcript splicing from exon 5 into an intron 5 sequence that lies ~5.7 kb downstream of the poly adenylation (polyA) site for *Homer1a* mRNA [110]. The precise sequence contribution to the premature transcript termination for *Homer1a* and *Ania-3* is not known. Examination of the 30 kb intron 5 sequence of *Homer1* failed to reveal obvious contributing sequences and no conserved sequences have been reported 5' or 3' of the poly(A) sites for these IEG transcripts. Moreover, the human intron 5 of Homer1 did not provide any indication of highly conserved sequence islands that might function in the activity-dependent termination of transcripts within this intron [110]. However, the mRNA for IEG *Homer1* isoforms does contain several AUUUA repeats at their 3' UTRs that may be responsible for destabilizing interactions with ribosomal translational machinery. While not involved in premature termination of transcription, this sequence likely contributes to the characteristic IEG-like, fast decay of mRNA transduction exhibited by *Homer1a* and *Ania-3* [110].

Homers are regulated within addiction-related neural circuits by drugs of abuse

With the exception of the inducible, IEG, Homer1 isoforms, CC-Homer proteins are expressed in similar quantities in brain, but differ somewhat in their regional distribution [105–107,

144]. Relevant to addiction, Homer transcripts or proteins are present in many of the structures within mesocorticolimbic circuits that exhibit pathology in addiction [cf. 2,4,23,53,151–156]. CC-Homer and IEG Homer isoforms are found throughout the cerebral cortex [105,106]. Homers appear to be differentially distributed within hippocampus; Homer1b/c is localized to the CA1, CA2, CA3, dentate gyrus and subiculum, where Homer3a/b labeling is high in CA3, but intermediate in CA2 regions, respectively [106]. In contrast to CC-Homer1 isoforms, the induction of Homer1a reveals mRNA expression within the CA1, CA2 and CA3 regions, but not in the dentate gyrus [144]. Homer2a/b labeling is intense in CA1 and CA2, with intermediate labeling in the subiculum [106]. All three Homer isoforms, including the inducible forms, are located within the dorsal and ventral aspects of the striatum [105,106,144], and in the amygdala [157], but only Homer1 and Homer2 isoforms have been localized within thalamus [105,106]. In addition to these limbo-cortico-striatal structures, all three Homer isoforms are located within cerebellum [106] and while the expression of Homer3 within the olfactory bulbs is developmentally down-regulated, the expression of both Homer1 and Homer2 isoforms persist throughout development [106]. Within neurons, Homer proteins are localized predominantly in the soma and apical dendrites [102,105,144,158]. At a subcellular level, Homer proteins are enriched within the postsynaptic density (PSD) fraction, but are also present in the crude nuclear, synaptosomal and microsomal fractions [105,144]. Homer2 differs from the other Homer isoforms as it is also localized to the soluble fraction and the synaptic vesicle fraction [105], implicating these isoforms in drug-induced changes in vesicular trafficking of receptor proteins.

First characterized as a gene whose mRNA expression is up-regulated within 1–3 hours following the application of supra-physiological electrical stimulation of the hippocampus [102,104,150], an up-regulation in either *Homer1a* and/or *Ania-3* mRNA expression occurs within various cortical and limbic structures following various experimental manipulations relevant to drug addiction, including exposure to pharmacological and environmental stressors, as well as following the administration of a variety of drugs of abuse (see Table 1) [c.f. 145, 146]. *Homer1a* or *Ania-3* mRNA expression is increased within PFC and/or NAC upon acute injection of psychomotor stimulants [102,159–160], the hallucinogen LSD [161,162], nicotine [163], and the dissociative anesthetic phencyclidine [164]. While the repeated administration of cocaine or nicotine induces a tolerance in the capacity of the drug to elevate NAC *Homer1a* levels [160,163], the capacity of methamphetamine to elevate mRNA levels persists within PFC with repeated drug treatment [159]. Similarly, *Ania-3* mRNA is up-regulated within frontal cortex by morphine in dependent animals, and this effect is observed also following naloxone-precipitated withdrawal [165]. A recent report by Zhang and colleagues [166] extended earlier data for cocaine-induced changes in *Homer1a* mRNA by demonstrating a transient (2–12 hrs), dose-dependent increase in Homer1a protein within both the dorsal and ventral aspects of the striatum following acute drug administration (see Table 2). Consistent with these data, immunoblotting studies in our laboratory have failed to detect changes in Homer1a levels within the PFC, NAC, dorsal striatum or hippocampus of either rats or mice at 3 weeks withdrawal from repeated cocaine injections (Table 2) [228]. Thus, while many drugs of abuse increase corticoaccumbens IEG Homer expression, this drug effect is transient and independent of a particular mechanism of drug action. In contrast to IEG Homers, the regulation of corticoaccumbens CC-Homer expression by drugs of abuse is more complex (Table 2) [39,157,166–170] and, as will be discussed below in greater detail, may reflect a compensatory response to either the immediate or longer-term effects of drug administration upon corticoaccumbens glutamate transmission.

Homer regulation of corticoaccumbens glutamate *in vivo*

Originally hypothesized to serve as a protein scaffold that facilitated intracellular signaling through Group1 mGluRs and calcium-related interactions between these receptors and

ionotropic NMDA receptors [e.g., 102,104,133,139], it is now clear that Homer proteins function to regulate many aspects of the functional architecture of glutamatergic synapses. As discussed above, Homers interact via their EVH1 domains with a wide variety of proteins and thus, function not only to scaffold receptors and ion channels on the plasma membrane to the cytoskeleton and intracellular signaling complexes, but also to regulate the function of plasma membrane ion channels and intracellular messenger systems that impact cellular signaling and cell excitability [c.f., 145–149]. Moreover, Homer protein interactions with other cytosolic scaffolding proteins, in particular Shank, are necessary for morphological aspects of glutamate synapses [145,171; see below]. Despite a decade of *in vitro* studies, our understanding of the role for Homer proteins in regulating neurotransmission *in vivo* is limited to phenotypic studies of *Homer* transgenic and null mutant mice (see Table 3). Nevertheless, the *in vivo* data are consistent with an important role for the Homer family of proteins in regulating the synaptic architecture and physiology of glutamate neurons in brain [c.f., 145–147,149], which are theorized to be involved in regulating addiction vulnerability [148].

Homer knock-out (KO) mice exhibit a number of abnormalities in corticofugal glutamate transmission, some of which depend upon the deleted gene. Both *Homer1* and *Homer2* KO mice exhibit an approximately 50% reduction in NAC basal extracellular levels of glutamate [34,38,172]. Importantly, restoration of NAC *Homer2* levels via the local infusion of an adeno-associated viral vector (AAV) carrying *Homer2b* cDNA normalizes glutamate levels in *Homer2* KO mice, supporting an active role for this CC-Homer isoform in regulating basal NAC glutamate content [34,38]. Interestingly, *Homer2* deletion does not affect basal glutamate content within the PFC, while *Homer1* deletion elevates PFC glutamate content by approximately 50% [34,172,173]. AAV-mediated transfection of PFC neurons with *Homer1c* cDNA, but not *Homer1a* cDNA, restored PFC basal glutamate levels to wild-type (WT) controls, implicating CC-Homer1 isoforms in regulating extracellular glutamate levels within this region [173]. At the present time, it is not entirely clear how deletion of *Homer* genes lead to such pronounced changes in basal glutamate content within the corticoaccumbens pathway. NAC extracellular glutamate levels are regulated primarily through a sodium-independent cystine-glutamate antiporter, system Xc- [174]. *Homer2* deletion attenuates NAC cystine-glutamate antiporter function, a finding attributed to reduced protein expression of the Xc- catalytic subunit [34]. As the cystine-glutamate antiporter does not contain the PPSPF necessary for Homer binding, it is likely that Homer regulation of antiporter function is indirect. Stimulation of presynaptically localized mGluR1 receptors leads to elevations in extracellular glutamate levels within both the NAC and PFC [169,175]. While *Homer2* deletion reduces the total mGluR1 protein expression within the NAC and reduces agonist-stimulated glutamate release within this region [34], recent immunoblotting studies conducted on *Homer1* WT and KO mice have failed to detect genotypic differences in Group1 mGluR expression within any brain region examined (Table 3) [176]. Thus, the effects of *Homer1* deletion upon basal glutamate content can be dissociable from effects upon Group1 mGluR function/expression. Homers regulate the plasma membrane trafficking of NMDA receptors via interactions with a trimeric Shank-GKAP-PSD95 complex that binds to NR2 subunits of the NMDA receptor [138,139,151]. While neither deletion of *Homer1* nor *Homer2* alters total NMDA receptor subunit expression within the NAC or PFC (Table 3) [34,176], *Homer2* deletion reduces the NAC plasma membrane expression of NR2a and NR2b NMDA receptor subunits *in vivo* [38]. Through the Shank-GKAP-PSD95 complex, NR2 subunits colocalize with nitric oxide synthase-1 (NOS-1) [177–179], an enzyme responsible for the synthesis of the retrograde messenger nitric oxide (NO) [180,181]. Thus, one testable hypothesis to account for the effects of Homer deletion upon basal and stimulated corticoaccumbens glutamate transmission relates to alterations in NMDA-mediated NO retrograde signaling [182,183]. While the precise molecular mechanisms involved in Homer regulation of corticoaccumbens glutamate transmission remain elusive, it is clear from the phenotypic characterization of *Homer* mutant mice that this family of proteins is necessary for the normal regulation of

corticoaccumbens glutamate transmission in vivo. The putative role for abnormalities in corticoaccumbens glutamate transmission in addiction (see above) render members of the Homer family of proteins likely molecular candidates in the pathophysiology of this disorder.

Potential role for Homers in drug-induced alterations in structural plasticity

Mounting evidence supports the theory that the addicted state results from a drug-induced usurpation of the cellular and molecular mechanisms underlying other forms of synaptic plasticity (e.g., learning and memory) within the neural circuits underlying motivation and psychomotor activation [c.f., 184,185]. Moreover, the chronic nature of addiction suggests that drug-induced structural plasticity within these neural circuits endures for months, if not years, following cessation of drug administration [184,185]. Indeed there exists now considerable data supporting persistent effects of various drugs of abuse upon neuronal morphology, particularly in the structural plasticity of dendritic spines of neurons within the PFC and NAC. Dendritic spines are highly motile, tiny membrane protuberances that are the postsynaptic contact site for the vast majority (>90%) of excitatory synapses in the brain. One cardinal feature of dendritic spine is the postsynaptic density (PSD), an electron-dense fibrous structure, consisting of clusters of neurotransmitter receptors, receptor-associated scaffolding and signaling proteins, as well as high concentrations of cytoskeletal proteins that cross-link actin filaments with the plasma membrane, the PSD, and the smooth endoplasmic reticulum present in some spines [122,186–191]. Experience-dependent changes in spine shape, size and number contribute to alterations in synaptic strength, in part by regulating connective opportunities [192–194] and neuronal morphology, as well as the ability to induce morphological changes within dendritic spines depends upon an intact cytoskeleton [197]. Increases in spine size, emergence of new spines and the perforation of the PSD are all thought to reflect spine head splitting and synapse duplication, contributing to a long-lasting enhancement of synaptic efficacy [e.g., 192–197].

While the effects of repeated drug experience upon structural plasticity within the corticoaccumbens glutamate pathway have been examined for a number of drugs of abuse, the large majority of studies assessed the long-term consequences of repeated cocaine or amphetamine exposure upon dendritic morphology [for review, 184]. In all studies to date, both non-contingent and contingent cocaine or amphetamine administration were found to increase spine density, as well as dendritic branching on medium spiny GABAergic neurons within both the shell and core subregions of the NAC [198–207]. Similarly, repeated treatment with both psychomotor stimulants increase spine density and branching of the apical, and to a lesser extent the basilar, dendrites of glutamatergic pyramidal neurons within the PFC [198–201,204,205]. These structural data are consistent with greater levels of filamentous actin (F-actin) within the NAC following both acute exposure to and withdrawal from repeated cocaine exposure [129]. As observed for psychomotor stimulants, nicotine also increases spine density in both PFC and the shell subregion of the NAC [208,209]. The structural changes induced by the above drugs are detectable at 24–48 hrs following discontinuation of chronic drug treatment [207] and can be observed for up 3.5 months [202,209]. Similar to nicotine and psychomotor stimulants, the structural plasticity associated with morphine treatment has been described a month after the last treatment [210,211]. However, the morphological changes induced by chronic morphine experience are very different from those induced by nicotine and stimulant drugs, characterized by marked decreases in spine density in both the shell of the NAC and medial PFC and decreased dendritic branching [210,211]. More well-characterized for hippocampus, chronic alcohol produces yet another distinct set of morphological changes within dendrites, compared to other drugs of abuse [212–215], characterized by increases in the ratio of wide and stubby spines to thin and mushroom-shaped spines [212–214]. A recent study of the effects of chronic alcohol consumption (14 weeks exposure) revealed a number of dendritic abnormalities within the NAC, including a decrease in spine density, a thickening

of the spine head and a disturbance in spine orientation [215]. Moreover, a subpopulation of medium spiny neurons also exhibited multi-headed spines (bifurcates and triplicates emerging from a common neck) and stacked-head spines, which resembled beads on a string with one head growing out of the other in serial arrangement [215] – abnormalities observed also following repeated psychomotor stimulant drug administration [205]. In both the case of the NAC and hippocampus, the alcohol-induced increases in dendritic spine head size was accompanied by increased synaptic targeting of NMDA receptors and clustering with PSD-95, as well as an enlargement in PSD-95-associated F-actin clusters [214–216]. Taken together, these data support the hypothesis that chronic drug exposure engages homeostatic responses that alter the dendritic processing of glutamate, and other neurochemical signals, ultimately affecting synaptic efficacy within key brain regions regulating the addictive properties of drugs of abuse [123,184,185,216].

Homers are critical for regulating dendritic morphology and thus, these proteins are likely candidates involved in the morphological abnormalities produced by repeated drug experience. The co-transfection of Homer1b with Shank1b in developing hippocampal neuronal cultures induces the maturation of spines and causes an enlargement in dendritic spine size, compared to the transfection of either protein alone [140,145;172]. Moreover, co-transfection of Homer1b with Shank1b also recruits IP3Rs and endoplasmic cisternae to the PSD [140,172]. The maturation and enlargement of spines requires the physical interaction of Homer and Shank as co-transfection of Homer1b with a mutant form of Shank that is incapable of binding Homer or the co-transfection of Shank1b with the truncated Homer1a did not alter spine size or shape [140,172]. Within the PSD, CC-Homer proteins colocalize with F-actin/Shank/PSD-95/GKAP/NMDA receptor clusters [132,147]. Corresponding to the maturation and enlargement of dendritic spines by Homer-Shank interactions [e.g., 145] is the recruitment of the NR2b subunit of the NMDA receptor, as well as, a number of other scaffolding and signaling molecules associated with glutamate receptors, including GKAP, PSD-95, IP3Rs, F-actin and various proteins related to the endoplasmic reticulum cisterna [132,140,145–147,151,172]. In mature neurons, the distribution and clustering of CC-Homers within dendritic spines is regulated by neuronal activity. High potassium-stimulated neuronal depolarization and subsequent fast, transient calcium entry induces the translocation of CC-Homers to spines and a marked increase in the number of Homer-NMDA receptor punctae [218]. Moreover, calcium entry via voltage-gated calcium channels also stimulates CC-Homer-NMDA clustering [218]. In contrast, the application of glutamate and stimulation of calcium entry through NMDA receptors causes Homer de-clustering and reduces the amount of CC-Homer-NMDA punctae within the spine [218]. While activation of protein kinase C (PKC) does not affect the intracellular distribution of CC-Homers, it induces the recruitment of Homer1a from the soma to the dendritic spine [218], a process expected to weaken synaptic efficacy. Thus, the regulation of calcium influx, in particular the kinetics of calcium entry, appears to be an important determinant in the localization of Homers to the PSD.

The formation of Homer-containing multi-protein clusters is developmentally regulated [132,220]. In one study by Shiraishi et al. [132], image analysis of developing hippocampal neuronal cultures revealed the localization of Homer2/NR2B/PSD-95 clusters along the soma and proximal dendrites at 7 days in vitro (DIV) and these clusters migrated towards the dendritic head and developing spines by 21 DIV, where they co-localized with F-actin [132]. In another study, the size of Homer1c/PSD-95 clusters increased progressively between 11–17 DIV and newly formed dendrites rapidly accumulated Homer1c. The density of Homer1c/PSD-95 clusters can be enhanced by activation of the protein kinase cAMP-dependent kinase (PKA) [220], furthering the evidence that neuronal activity regulates the translocation of Homer proteins to dendritic spines. While not yet assessed in developing cortical neurons, both IEG and CC-Homers play a critical role in axonal pathfinding in optical tectal neurons [221]. Transfection of this neuronal type with Homer1a, Homer1c or a mutant of Homer1c that

interferes with the EVH1-binding domain on interacting proteins induces aberrant axonal projections and irregular dendritic arborization, while transfection with a mutant for Homer1a that does not interact with the EVH1-binding domain on interacting proteins prevented alterations in neuronal morphology and the alterations in axonal trajectories. Thus, there appears to be an optimal level of functional CC-Homer required in the growth cone for normal axonal pathfinding [221] and it is tempting to speculate that early environmental insults might alter Homer expression and produce abnormalities in neuronal orientation, morphology and axonal connections, as reported in the brains animals exposed prenatally to drugs of abuse or stress [e.g., 185,222].

Homers and cocaine-induced neuroplasticity

Obligatory for the production and maintenance of many of the enduring neuroadaptations produced by exposure to cocaine, drug-induced abnormalities in corticoaccumbens glutamatergic projections produce the key behavioral characteristic of cocaine addiction [for reviews, 2,4,19,23,223]. As discussed above, repeated cocaine exposure elicits numerous alterations in corticoaccumbens glutamatergic function that include alterations in NAC basal glutamate content [e.g., 47,34,35], a sensitized NAC and PFC glutamate response to a cocaine challenge injection [e.g., 31,32,35,37,52] and complex alterations in both the function and expression of iGluRs, mGluRs and glutamate transporters [for reviews, 2,4,18,20,224–227]. As Homer isoforms regulate both pre- and postsynaptic aspects of glutamatergic signaling within this pathway [c.f., 145–149], these proteins are likely molecular candidates mediating the cocaine-induced glutamatergic abnormalities contributing to the addictive and psychomotor-activating properties of this drug [148].

As presented in Table 1, the mRNA for IEG Homer1 isoforms is up-regulated within 1–3 hours in brain following an acute cocaine injection [102,160,166]. In dorsal striatum, nucleus accumbens and frontal cortex, the elevation in Homer1a protein expression by an acute injection of cocaine resembles that of the IEG C-Fos, is dose-dependent and correlates with the magnitude of locomotor hyperactivity exhibited by rats [166]. By inhibiting plasma membrane transporters, cocaine prevents the re-uptake of dopamine, serotonin and norepinephrine and thus, enhances levels of these neurotransmitters within the synapse [228]. Pretreatment of animals with the selective D1 receptor antagonist SCH23390, but not the selective D2 receptor antagonist eticlopride, prevents the cocaine-induced rise in striatal Homer1a protein expression supporting a key role for D1 receptor signaling in mediating this effect [166]. Moreover, in striatal cultures, a dopamine-induced induction in Homer1a expression could be mimicked by the protein kinase A (PKA) activator 8-bromo-cAMP and attenuated by the PKA inhibitor H89, the calcium/calmodulin-dependent protein kinase (CaMK) inhibitor KN62 or anti-sense oligonucleotides against the transcriptional regulator CREB (cAMP response element binding protein) [166]. These data provided the first insight into the intracellular signaling cascade(s) involved in the regulation of *Homer1a* transcription and point to an important role for dopamine D1 receptor-mediated activation of CREB in this regard [166].

The cocaine-induced rise in *Homer1a* mRNA and protein expression is transient, dissipating within 6–12 hours following cocaine injection [102,166] and shows tolerance with repeated cocaine administration [160]. However, cocaine-induced changes in addiction-related behavior, as well as, pre- and postsynaptic alterations in corticoaccumbens glutamate transmission are either absent or minimal during the first 1–3 days immediately following treatment, but are detectable after longer withdrawal periods [for reviews, 19,20,22]. Moreover, for certain cocaine-induced phenomena (e.g., motor hyper-activity, reinstatement of drug-seeking, accumbens glutamate sensitization), the drug effect can intensify with the passage of time and persist for months following the end of cocaine treatment [e.g., 19–21,114]. While

the induction of striatal Homer1a expression may be involved in mediating the acute locomotor-activating properties of the drug, there exists no clear temporal relationship between cocaine's effects upon Homer1a expression and the manifestation of cocaine-induced neuroplasticity. However, consistent with earlier reports for the interactions between IEG and CC-Homer *in vitro* [145,147,149], the induction of Homer1a by cocaine disrupts CC-Homer-Group1 mGluR interactions as well as CC-Homer-IP3 receptor interactions *in vivo* [166]. This raises the possibility that the relatively short-lived elevation in Homer1a by acute cocaine may allow for a rearrangement of the architecture of glutamatergic synapses, thereby initiating or enabling drug-induced plasticity within brain regions embedded within neural circuitry of addiction.

In contrast to IEG Homer isoforms, delayed changes in CC-Homer expression are produced within limbic regions following repeated non-contingent cocaine administration that coincide with the manifestation of behavioral and neurochemical sensitization to this drug (see Table 2) [169,229]. Repeated injections of cocaine, followed by a 1–3 week period of withdrawal, augments the acute psychomotor-activating effects of the drug, a phenomenon referred to as behavioral sensitization [e.g., 19,20–22]. Immunoblotting conducted on tissue from Sprague Dawley rats indicated a coincident reduction in mGluR5 and Homer1b/c protein levels at 3 weeks withdrawal from repeated cocaine administration that was selective for the medial, but not the lateral, aspect of the NAC [169]. Identical cocaine treatment to C57BL/6J mice revealed a concomitant reduction in NAC levels of Homer1b/c and Homer2a/b, indicating that CC-products of both the *Homer1* and *Homer2* genes are similarly regulated within NAC by cocaine withdrawal (Fig. 2) [229]. As observed previously in the earlier rat study by Swanson et al. [169], PFC Homer1b/c levels were unchanged following withdrawal from repeated cocaine in mice; however, we observed an approximately 30% increase in PFC Homer2a/b expression (Fig. 2). Thus, repeated non-contingent, experimenter-administered cocaine elicits enduring, but opposite effects, upon Homer2a/b expression within the cell body and terminal regions of the corticoaccumbens glutamate pathway [229]. The regulation of mesolimbic Homer protein expression by cocaine has also been assessed in a “long access” animal model of addiction in which groups of animals are allowed to self-administer intravenous cocaine daily for either 1 hr or 6 hrs [e.g., 230–232]. These two self-administration paradigms elicit very different patterns of cocaine intake (stable vs. escalating, respectively) [e.g., 230] and result in very different neuroadaptations, as revealed by both behavioral and biochemical assays [230–237]. The effects of a history of cocaine self-administration upon corticoaccumbens CC-Homer expression are complex, dependent upon the duration of cocaine access, the duration of withdrawal and the region investigated (Table 2) [167,237]. As summarized in Table 2, the level of Homer1b/c, but not Homer1a, is reduced within the core subregion of the NAC at 24 hrs withdrawal from either 1-hr or 6-hrs of cocaine self-administration and this effect dissipated by 2 weeks withdrawal. Short-term withdrawal from cocaine self-administration moderately reduced NAC Homer2a/b levels in both cocaine self-administering groups, but in contrast to Homer1b/c, this effect intensified with the passage of time (Table 2) [237]. In contrast to the selective effects of non-contingent cocaine injections upon PFC Homer2a/b expression [229], withdrawal from intravenous cocaine self-administration affected only PFC levels of Homer1b/c (Table 2) [167]. At 24 hrs withdrawal, an elevation in PFC Homer1b/c expression was observed in long-access animals but this effect was no longer apparent at 2 weeks withdrawal, whereas no change in PFC Homer1b/c levels was observed at 2 hrs withdrawal in short-access animals but were significantly reduced at the 2 week time-point. It is clear that considerable work remains to understand the factors affecting and the mechanisms through which withdrawal from repeated cocaine experiences regulate the expression of CC-Homer isoforms in brain. However, as the changes in CC-Homer expression produced by withdrawal from repeated non-contingent or response-dependent cocaine administration are paralleled by changes in corticoaccumbens the function of expression of iGluR and mGluR expression/function [167,169,237], drug-induced alterations in glutamatergic signaling through Homer

complexes may be important cellular adaptations to cocaine that contribute to the enduring consequences of repeated drug exposure upon brain and behavior.

Indeed, recent studies have established an important role for CC-Homer proteins in regulating sensitivity to the behavioral and neurochemical effects of cocaine. *Homer1* and *Homer2* KO mice exhibit enhanced cocaine-induced place-conditioning and cocaine-induced locomotor activity, and *Homer2* KO mice exhibit a shorter latency to acquire a lever-press response for intravenous cocaine, than do WT mice [34]. Similarly, a reduction in NAC Homer1b/c levels, produced by infusion of anti-sense oligonucleotides against *Homer1*, elicits a sensitized motor response in cocaine-naïve rats given an acute cocaine injection [238]. In cocaine-naïve *Homer1* and *Homer2* KO mice, the increases in behavioral sensitivity to cocaine are accompanied by a reduction in NAC glutamate content and an enhanced capacity of cocaine to elevate NAC glutamate levels [34,172]. Moreover, *Homer2* KO mice exhibit a reduction in the function and expression of both Group1 mGluRs and the cystine-glutamate transporter [34]. These behavioral and neurochemical alterations are akin to those observed in rodents with a history of repeated cocaine administration [e.g., 19,22,31,35,47,57,169], indicating that a reduction in CC-Homer1 and CC-Homer2 expression can elicit a “pre-sensitized” cocaine phenotype. In contrast to *Homer1* and *Homer2* gene products, Homer3 isoforms are localized primarily to hippocampus and cerebellum [105,106]. While both acute and repeated cocaine elevates cerebellar Homer3a/b expression [239], *Homer3* KO mice do not exhibit a cocaine “presensitized” behavioral phenotype [34]. While transgenic mice over-expressing Homer1a within striatal striosome patches exhibit increased locomotor sensitivity in response to an acute challenge injection of amphetamine [240], AAV-mediated over-expression of Homer1a within the NAC or PFC does not alter the acute or the sensitized locomotor response to cocaine [35, 173]. However, AAV-mediated restoration of Homer2b to the NAC of *Homer2* KO mice reversed genotypic differences in cocaine-conditioned reward and motor activity [34] and either AAV- or TAT-mediated over-expression of Homer1c or Homer2b in the NAC of repeated cocaine-treated rats prevented the expression of cocaine-induced behavioral and glutamate sensitization when assessed at 3 weeks withdrawal from repeated cocaine exposure [35]. As repeated cocaine administration can produce a time-dependent down-regulation in CC-Homer1 and -Homer2 isoforms within the NAC (Fig. 1) [167,169,229,237], this collection of data for the NAC indicates cocaine-induced changes in CC-Homer1 and -Homer2 isoforms as important regulators of cocaine-induced neuroplasticity within this region.

Although withdrawal from repeated cocaine does not alter PFC basal glutamate content [47], it sensitizes the capacity of a challenge injection to elevate glutamate levels in this region [37]. Despite the pronounced abnormalities in NAC glutamate, *Homer2* KO mice do not exhibit alterations in basal or cocaine-stimulated glutamate release within the PFC [34]. In contrast, the cocaine “pre-sensitized” phenotype of *Homer1* KO mice is accompanied also by an approximately 50% elevation in basal levels of glutamate and a blunting of the cocaine-induced rise in extracellular glutamate within the PFC [172]. Infusion of AAV-Homer1c to the PFC of *Homer1* KO mice reverses the elevated basal glutamate content, while infusion AAV-Homer1a had no effect [173]. Additionally, infusion of AAV-Homer1c, but not -Homer1a, reversed the genotypic difference in cocaine-induced elevations of glutamate in the PFC [173], indicating that cocaine-stimulated glutamate release within the PFC requires Homer1c. However, an intra-PFC infusion of AAV-Homer1a blunted the capacity of cocaine to elevate PFC glutamate in WT mice and reduced glutamate levels below baseline in KO animals, indicating an active and inhibitory role for this IEG isoform in cocaine-stimulated glutamate release [173]. Thus, cocaine-induced imbalances between IEG and CC-Homer expression may contribute to the enduring abnormalities in prefrontal cortex function observed in cocaine addicts and consistent with this notion, a single-nucleotide polymorphism on the first intron of *Homer1* (rs6871510) has been significantly associated with cocaine dependence in an African American population [241].

Homers and alcohol-induced neuroplasticity

Alcohol is a drug of abuse that inhibits iGluR and Group1 mGluR (mGluR5) receptor function [e.g., 242–244] and many of the acute behavioral effects of alcohol are related to the inhibition of glutamate receptor signaling within the mesocorticolimbic and extended amygdala circuits [for reviews, 123,127,153,216]. The dose-response function for acute alcohol-induced changes in corticoaccumbens extracellular glutamate is biphasic; lower doses either do not change or increase glutamate levels, while moderate to higher doses reduce glutamate levels [39,64,168,245]. Repeated alcohol administration alters basal glutamate content in the NAC [e.g., 38,246–248] and sensitizes the capacity of alcohol to elevate extracellular glutamate levels, at least within the NAC [38,39,249–251]. Moreover, repeated alcohol administration produces an enduring up-regulation in both iGluR and mGluR expression, function, as well as increased glutamate receptor trafficking to, and clustering within, the plasma membrane [39,123,213–216,252–254]. As these neuroadaptations are implicated in the development of alcohol dependence, tolerance, and addiction [123,127,148,153,214–216], recent immunoblotting studies examined the consequences of repeated alcohol exposure upon the protein expression of Homer isoforms within the NAC. Alcohol-experienced C57BL/6J mice revealed a pronounced (2.0–2.5-fold increase) and selective up-regulation in Homer2 protein expression within the NAC following various alcohol treatment regimens, including alcohol injection [255], chronic (3 month) continuous alcohol consumption [39] and repeated, binge alcohol intake [256] (Table 2). The capacity of alcohol to elevate NAC Homer2 levels is injection number-dependent, suggesting that this molecular adaptation is a direct pharmacological response to the drug [255]. Moreover, the approximately 2.5-fold increase in NAC Homer2 levels produced by a 3-month history of continuous alcohol drinking is very persistent and is unchanged at from 2 days to 2 months following the last drinking session [39]. Finally, under continuous and/or binge drinking conditions, the rise in Homer2 levels was accompanied by elevations in the total protein expression of Group1 mGluRs and NR2 subunits, as well as the activation of PI3K and PKC ϵ [39,256], two down-stream intracellular mediators of Group1 mGluR signaling [142,257]. Thus, alcohol up-regulates the NAC expression of members of the mGluR-Homer-NMDA signaling complex and increases the activation of mGluR-Homer-mediated signaling cascades. Since alcohol is an antagonist at both NMDA and mGluR5 receptors [242–244], we propose that the observed up-regulation in glutamate receptor/Homer expression and kinase activation likely reflects a compensatory response to glutamate receptor blockade by alcohol. As chronic alcohol administration down-regulates ubiquitin-mediated degradation systems [e.g., 258,259], the persistence of alcohol's effects upon Homer and glutamate receptor expression might reflect decreased protein degradation, by virtue of alcohol's effect upon the ubiquitin system, Homer tetramerization, or both [39].

Neural and behavioral genetic studies support an important role for Homer proteins in regulating sensitivity to the behavioral and neurochemical effects of alcohol [38,39,260]. *Drosophila* Homer (D. Homer) is highly homologous to mammalian Homer1 proteins [261] and recent behavioral screens for *Drosophila* mutants revealed that *Drosophila* lacking *Homer* (*homer*^{R102}) exhibit increased sensitivity to the acute sedative effects of alcohol and fail to develop normal levels of rapid tolerance upon a subsequent alcohol exposure. In support of an active role for Homer in regulating alcohol sensitivity, pan-neuronal expression of WT Homer reduced their initial sensitivity to acute alcohol and restored the development of rapid tolerance [260]. These data for *Drosophila* are consistent with our earlier reports for altered alcohol sensitivity in mice lacking *Homer2* [38]. *Homer2* KO mice exhibit an alcohol-avoiding and -intolerant behavioral phenotype that is characterized by: alcohol-conditioned place-aversion, shifts to the right and down in the dose-response functions for alcohol preference and intake, increased alcohol-induced sedation and a lack of tolerance to the locomotor-inhibiting effects of alcohol upon repeated alcohol administration. While *Homer2* deletion does not alter the capacity of acute alcohol to affect NAC glutamate levels, KO mice fail to exhibit glutamate

sensitization when treated repeatedly with alcohol [38]. AAV-mediated restoration of Homer2b to the NAC of *Homer2* KO mice completely reverses the alcohol behavioral and neurochemical phenotype of KO animals, supporting a link between alcohol reward and NAC glutamate sensitization [38]. Mimicking the effect of alcohol upon NAC Homer2 protein expression via AAV-mediated Homer2b over-expression in the NAC of WT mice on a C57BL/6J X 129sV/J genetic background enhances alcohol preference under free-access conditions in the home cage [38] and NAC over-expression of Homer2b in alcohol-preferring C57BL/6J mice facilitates the development of an alcohol-conditioned place-preference and shifts the alcohol-response functions for lever-pressing for alcohol, response-contingent alcohol consumption and alcohol preference in the home cage up and the left of control animals [38, 39]. Moreover, NAC Homer2 over-expression in C57BL/6J mice facilitated the development of tolerance to the locomotor-impairing effects of alcohol and augmented both the acute and sensitized glutamate response to alcohol [39]. Collectively, the immunoblotting and behavioral genetic studies to date implicate an up-regulation in NAC Homer2 expression as an important cellular adaptation to alcohol facilitating alcohol-induced changes in behavior, including alcohol drinking.

Homers and methamphetamine

Methamphetamine is the N-methylated analogue of amphetamine and is widely considered to be more potent and to have higher potential for addiction [262]. Like other amphetamines, methamphetamine increases extracellular levels of monoamines by disrupting vesicular storage and reversing the plasma membrane transporter [262–264]. While methamphetamine's effects upon the monoaminergic systems have received considerable experimental attention [for reviews, 264–270], less is known regarding the regulation of corticoaccumbens glutamate and glutamate receptor expression by amphetamine and methylated analogs. Acute administration of amphetamines is reported to produce either no change or a delayed rise in extracellular glutamate levels within striatal regions [59–62, 271, 272], while an acute injection of methamphetamine, but not amphetamine, elevates PFC glutamate levels [271]. Whereas repeated cocaine administration produces robust drug-induced glutamate sensitization within the NAC [e.g., 31, 35, 47, 57], repeated dosing with non-toxic regimens of amphetamine or methamphetamine elicits little effect upon the capacity of these drugs to alter glutamate levels within the corticoaccumbens pathway [61, 272]. In contrast, repeated high dose amphetamine or methamphetamine regimens that induce dopamine neurotoxicity produce an increase in glutamate content within the PFC [273], a delayed increase in dorsal and ventral striatal glutamate levels [60, 274–277] and enhance potassium-stimulated, but not methamphetamine-stimulated, glutamate release within the PFC [277]. Whether or not the more modest effects of amphetamine regimens upon corticoaccumbens glutamate relate to the duration of withdrawal remains to be determined. In support of this possibility, reductions in the mRNA or protein expression of the AMPA receptor subunits GluR1 and GluR2, and the obligatory NMDA subunit NR1 within the NAC are observed at 14 days withdrawal, but not at earlier time-points [278–281]. In contrast, changes in glutamate receptor subunit expression are apparent within the PFC during early withdrawal [278–282]. Of note, the amphetamine-induced changes in glutamate receptor subunit expression appear to be opposite to those reported previously for repeated cocaine [e.g., 283–285]. Thus, while cocaine and methamphetamine exert *qualitatively* similar effects upon extracellular monoamine levels [227, 262, 264], the enduring effects of these two psychomotor stimulants upon corticoaccumbens glutamate transmission are quite different [for review, 20].

Similar to acute cocaine [102, 160, 166], an acute injection of methamphetamine elevates *Homer1a* mRNA expression in brain [159], which would be predicted to contribute to the acute psychomotor-activating effects of this drug [166]. While the capacity of methamphetamine to elevate *Homer1a* mRNA levels persists with repeated drug treatment, it does not increase with

the development of behavioral sensitization [159]. Thus, like cocaine [238], the effects of repeated methamphetamine administration upon *Homer1a* mRNA expression do not easily account for this form of behavioral plasticity. A recent examination for the effects of repeated low dose (10×1 mg/kg) methamphetamine administration upon NAC Homer protein expression failed to detect changes in Homer1a/b/c or Homer2a/b at 24 hrs withdrawal. However, in contrast to repeated cocaine [169,228,237], repeated methamphetamine induces a marked increase in the NAC protein expression of all of these isoforms at 3 weeks withdrawal from repeated methamphetamine treatment (Table 2) [286]. These latter findings are more akin to those observed in mice treated repeatedly with alcohol [39,255,256], raising the possibility that the methamphetamine-induced reduction in glutamate receptor expression/function or other enduring deficits in corticoaccumbens glutamate transmission [e.g., 272,278–282] may elicit a compensatory rise in Homer expression. Deletion of either the *Homer1* or *Homer2* genes increases sensitivity to the psychomotor-activating effects methamphetamine [172], in a manner akin to that for cocaine [34,173]. While a cocaine-induced reduction in NAC CC-Homer expression is necessary to develop cocaine-induced behavioral and neurochemical sensitization [35], the functional consequences of the methamphetamine-induced increase in NAC Homer expression for methamphetamine-induced neuroplasticity remain elusive. However, as the data to date indicate that drug-induced changes in NAC Homer protein expression actively regulate the rewarding/reinforcing and/or psychomotor effects of cocaine and alcohol [34,35,39,173], methamphetamine-induced changes in NAC Homer protein expression may be involved in the enduring changes in behavioral sensitivity produced by this potent, psychomotor stimulant drug.

Stressor-induced regulation of Homers: implications for addiction vulnerability and relapse

Stress is highly implicated in the etiology of addiction and stressors are considered major precipitating factors in relapse to drug-seeking and -taking [c.f., 152,153,222,287–295]. Like repeated drug administration (see above), repeated exposure to stressors induces morphological abnormalities within glutamatergic pyramidal neurons within the cortex of laboratory animals [e.g., 184,221,296–298]. Both psychological and physiological stressors can elevate corticoaccumbens glutamate levels [299–301] and repeated maternal stress elicits “cocaine-like” alterations in basal and cocaine-stimulated glutamate release within the NAC of adult offspring in conjunction with a “pre-sensitized” cocaine behavioral phenotype [295]. Evidence that stressors can affect the expression of Homers in brain was first described in the seminal report by Kato et al. [150], in which a modest rise in *Homer1a* mRNA expression was detected within hippocampal homogenates at 3 hrs following the systemic administration of the pharmacological stressors pentylenetetrazole and cycloheximide. Similarly, exposure to a mild stressor such as placement into a novel environment also augments *Homer1a* mRNA within hippocampus, as well as within parietal cortex [302]. Intriguingly, Igaz et al. [303] reported no change in Homer1a protein expression within the hippocampus at 3 hours following delivery of a mild footshock in a one-trial aversive learning paradigm; however, Homer1a protein expression was found to be elevated in animals sacrificed 24 hours following shock delivery. This footshock-induced change in the pattern of Homer1a expression is very atypical for an IEG and is distinct from that produced by other forms of synaptic activity [102,150,302], raising the possibility that IEG Homers may regulate both the consolidation and recall of memories concerning stressful or aversive events [303].

In support of an enduring regulation of both IEG and CC-Homer expression by stressors, Homer1a, Homer1b/c and Homer2a/b protein levels were increased within the PFC, hippocampus and amygdala, while Homer1a levels were reduced in the striatum, of weanling offspring of rat dams subjected to repeated restraint stress during the last 7 days of gestation

[157]. As these changes in Homer protein expression were observed at 3 weeks following the last maternal restraint stress, these data provide evidence that repeated prenatal stress can elicit persistent changes not only in CC-, but also, IEG-Homer expression, which are likely to impact synaptic development, morphology and plasticity. It remains to be determined whether or not the prenatal stress-induced alterations in IEG and CC-Homer expression persist into adulthood. However, prenatally stressed animals exhibit profound cognitive, social and sensorimotor deficits [304,305] and increased sensitivity to the psychomotor-activating, motivational and glutamate-sensitizing effects of stimulant drugs as adults [294,295,306]. Interestingly, the behavioral and glutamate phenotype induced by prenatal stress bears striking resemblance to that produced by *Homer1* deletion [34,172,173,307]. Thus, stressor-induced imbalances in IEG- and CC-Homer expression within corticolimbic structures may alter the development trajectory of corticolimbic circuits, thereby increasing the propensity to develop addiction-related behaviors in later life [157,220].

Homers, addiction and schizophrenia co-morbidity

Patients with schizophrenia show alarmingly high rates of substance use disorders (20–65%) [308–313], as well as a considerably greater risk of developing a drug addiction disorder than individuals in the general population [314]. As reviewed in detail elsewhere [315], dually diagnosed schizophrenia patients typically present with more severe symptoms [308,309, 316–319], exhibit increased suicidal ideation [320,321], require more frequent hospitalizations [310,322], and experience more frequent relapses than patients without co-occurring substance abuse [323–325]. While analyses for polymorphisms in the *Homer* genes have not yet been assessed in a co-morbid population, single nucleotide polymorphisms in *Homer1* have been associated with cocaine addiction [241], as well as in schizophrenia (IVS4 + 18A > G in intron 4) [326]. In addition to exhibiting increased sensitivity to the rewarding and psychomotor-activating effects of psychomotor stimulants, *Homer1* KO mice exhibit a host of other behavioral abnormalities, including deficits in working memory, pre-pulse inhibition of acoustic startle, instrumental learning and habituation to a mild stressor, as well as increases in emotional reactivity to mild stressors and behavioral despair [34,172,173,307]. Moreover, *Homer1* KO mice exhibit increased behavioral sensitivity to NMDA receptor antagonists [34,38,172] and both the deficit in pre-pulse inhibition and the increased sensitivity to phencyclidine can be reversed by pretreatment with either typical or atypical antipsychotic drugs [172; Richardson and Szumlinski, in preparation]. Coupled with their abnormal PFC glutamate phenotype (see above), the behavioral phenotype of *Homer1* KO mice is consistent with an animal model of schizophrenia [172,173]. It is highly unlikely that a single high penetrant mutation in *Homer1* accounts for cocaine addiction, schizophrenia or their high rate of co-morbidity; however, it is tempting to speculate that particular combinations of polymorphisms within *Homer1* or perhaps other *Homer* genes may contribute to, or increase the probability of, patients with schizophrenia developing a co-morbid substance abuse disorder.

Conclusions

The Homer family of postsynaptic proteins is critical for regulating the architecture of glutamatergic synapses within the brain and for maintaining normal glutamate tone within the corticoaccumbens pathway. Both pharmacological and non-pharmacological factors affecting addiction regulate IEG and constitutively expressed members of the Homer family of postsynaptic proteins within this pathway, as well as within other limbic structures implicated in the neurobiology of addiction. Behavioral and neural genetic studies provide preclinical evidence to support an important and active role for Homers in regulating drug-induced neuroplasticity, as well as cognitive and emotional processes associated with an addicted state. A significant association of single nucleotide polymorphisms within *Homer1* with cocaine

addiction provides clinical support for *Homer* genes in addiction vulnerability and the continued application of mutational analysis techniques to examine for patterns of polymorphisms within the *Homer* gene family in addicted persons will provide opportunities to bridge preclinical and clinical knowledge regarding a role for these proteins in regulating addiction vulnerability and, perhaps also its treatment.

Acknowledgements

This work is supported, in part, by NIAAA grants AA-015351, AA-0135017 (INIA West) and AA-016650 (INIA West), the National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD) and the University of California at Santa Barbara Academic Senate.

Abbreviations

AAV	adeno-associated viral vector
CC	Homer- coiled-coil Homer
IEG	immediate early gene
KO	knock-out
mGluR	metabotropic glutamate receptor
NAC	nucleus accumbens
NMDA	N-methyl-D-aspartate
PFC	prefrontal cortex
PSD	postsynaptic density
VTa	ventral tegmental area
WT	wild-type

References

1. Bickel WK, Miller ML, Yi R, Kowal BP, Lindquist DM, Pitcock JA. Behavioral and neuroeconomics of drug addiction: Competing neural systems and temporal discounting processes. *Drug Alcohol Depend.* 2006;in press
2. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. *J Neurosci* 2002;22:3312–20. [PubMed: 11978805]
3. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. *Annu Rev Neurosci* 2006;29:565–98. [PubMed: 16776597]
4. Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. *Neuron* 2005;45:647–50. [PubMed: 15748840]

5. Dom G, Sabbe B, Hulstijn W, van den Brink W. Substance use disorders and the orbitofrontal cortex: systematic review of behavioural decision-making and neuroimaging studies. *Br J Psychiatry* 2005;187:209–20. [PubMed: 16135857]
6. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ, et al. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. *Am J Psychiatry* 2000;157:1789–98. [PubMed: 11058476]
7. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. *Am J Psychiatry* 2002;159:1642–52. [PubMed: 12359667]
8. Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC. Functional magnetic resonance imaging of cocaine craving. *Am J Psychiatry* 2001;158:86–95. [PubMed: 11136638]
9. Xiao Z, Lee T, Zhang JX, Wu Q, Wu R, Weng X, et al. Thirsty heroin addicts show different fMRI activations when exposed to water-related and drug-related cues. *Drug Alcohol Depend* 2006;83:157–62. [PubMed: 16406379]
10. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. *Neuroimage* 2005;26:480–92. [PubMed: 15907305]
11. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. *Neuropsychopharmacology* 2003;28:265–75. [PubMed: 12589379]
12. Crockford DN, Goodyear B, Edwards J, Quickfall J, el-Guebaly N. Cue-induced brain activity in pathological gamblers. *Biol Psychiatry* 2005;58:787–95. [PubMed: 15993856]
13. Goldstein RZ, Volkow ND, Chang L, Wang GJ, Fowler JS, Depue RA, Gur RC. The orbitofrontal cortex in methamphetamine addiction: involvement in fear. *Neuroreport* 2002;13:2253–7. [PubMed: 12488806]
14. Lingford-Hughes AR, Daglish MR, Stevenson BJ, Feeney A, Pandit SA, Wilson SJ, Myles J, Grasby PM, Nutt DJ. Imaging alcohol cue exposure in alcohol dependence using a PET 15O-H₂O paradigm: results from a pilot study. *Addict Biol* 2006;11:107–15. [PubMed: 16759343]
15. Grusser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, et al. Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. *Psychopharmacology* 2004;175:296–302. [PubMed: 15127179]
16. Okuyemi KS, Powell JN, Savage CR, Hall SB, Nollen N, Holsen LM, et al. Enhanced cue-elicited brain activation in African American compared with Caucasian smokers: an fMRI study. *Addict Biol* 2006;11:97–106. [PubMed: 16759342]
17. Tanabe J, Crowley T, Hutchison K, Miller D, Johnson G, Du YP, et al. Ventral striatal blood flow is altered by acute nicotine but not withdrawal from nicotine. *Neuropsychopharmacology*. 2007in press
18. Steketee JD. Cortical mechanisms of cocaine sensitization. *Crit Rev Neurobiol* 2005;17:69–86. [PubMed: 16808728]
19. Vanderschuren LJ, Kalivas PW. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. *Psychopharmacology* 2000;151:99–120. [PubMed: 10972458]
20. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. *Prog Neurobiol* 1998;54:679–720. [PubMed: 9560846]
21. Robinson TE, Berridge KC. Incentive-sensitization and addiction. *Addiction* 2001;96:103–14. [PubMed: 11177523]
22. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. *Brain Res Brain Res Rev* 1991;16:223–44. [PubMed: 1665095]
23. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. *Psychopharmacology* 2003;168:44–56. [PubMed: 12652346]
24. Schmidt HD, Anderson SM, Famous KR, Kumaresan V, Pierce RC. Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking. *Eur J Pharmacol* 2005;526:65–76. [PubMed: 16321382]

25. Sun W, Akins CK, Mattingly AE, Rebec GV. Ionotropic glutamate receptors in the ventral tegmental area regulate cocaine-seeking behavior in rats. *Neuropsychopharmacology* 2005;30:2073–81. [PubMed: 15841101]
26. Stewart J. Stress and relapse to drug seeking: studies in laboratory animals shed light on mechanisms and sources of long-term vulnerability. *Am J Addict* 2003;12:1–17. [PubMed: 12623736]
27. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. *Neurosci Biobehav Rev* 2004;27:827–39. [PubMed: 15019432]
28. Bowers MS, McFarland K, Lake RW, Peterson YK, Lapish CC, Gregory ML, et al. Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. *Neuron* 2004;42:269–81. [PubMed: 15091342]
29. Kozell LB, Meshul CK. Nerve terminal glutamate immunoreactivity in the rat nucleus accumbens and ventral tegmental area after a short withdrawal from cocaine. *Synapse* 2004;51:224–32. [PubMed: 14696010]
30. Li Y, Hu XT, Berney TG, Vartanian AJ, Stine CD, Wolf ME, et al. Both glutamate receptor antagonists and prefrontal cortex lesions prevent induction of cocaine sensitization and associated neuroadaptations. *Synapse* 1999;34:169–80. [PubMed: 10523754]
31. Pierce RC, Bell K, Duffy P, Kalivas PW. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. *J Neurosci* 1996;16:1550–60. [PubMed: 8778304]
32. Pierce RC, Reeder DC, Hicks J, Morgan ZR, Kalivas PW. Ibotenic acid lesions of the dorsal prefrontal cortex disrupt the expression of behavioral sensitization to cocaine. *Neuroscience* 1998;82:1103–14. [PubMed: 9466434]
33. Prasad BM, Hochstatter T, Sorg BA. Expression of cocaine sensitization: regulation by the medial prefrontal cortex. *Neuroscience* 1999;88:765–74. [PubMed: 10363816]
34. Szumlinski KK, Dehoff MH, Kang SH, Frys KA, Lominac KD, Klugmann M, et al. Homer proteins regulate sensitivity to cocaine. *Neuron* 2004;43:401–13. [PubMed: 15294147]
35. Szumlinski KK, Abernathy KE, Oleson EB, Klugmann M, Lominac KD, He DY, et al. Homer isoforms differentially regulate cocaine-induced neuroplasticity. *Neuropsychopharmacology* 2006;31:768–77. [PubMed: 16160706]
36. Tzschentke TM, Schmidt WJ. Functional heterogeneity of the rat medial prefrontal cortex: effects of discrete subarea-specific lesions on drug-induced conditioned place preference and behavioural sensitization. *Eur J Neurosci* 1999;11:4099–109. [PubMed: 10583498]
37. Williams JM, Steketee JD. Cocaine increases medial prefrontal cortical glutamate overflow in cocaine-sensitized rats: a time course study. *Eur J Neurosci* 2004;20:1639–46. [PubMed: 15355331]
38. Szumlinski KK, Lominac KD, Oleson EB, Walker JK, Mason A, Dehoff MH, et al. Homer2 is necessary for EtOH-induced neuroplasticity. *J Neurosci* 2005;25:7054–61. [PubMed: 16049182]
39. Szumlinski KK, Ary AW, Lominac KD, Kippin TE. Facilitation of alcohol-induced neuroplasticity by accumbens Homer2 over-expression. *Neuropsychopharmacology*. 2007in press
40. Ma YY, Chu NN, Guo CY, Han JS, Cui CL. NR2B-containing NMDA receptor is required for morphine-but not stress-induced reinstatement. *Exp Neurol* 2007;203:309–19. [PubMed: 17014848]
41. Tzschentke TM, Schmidt WJ. Discrete quinolinic acid lesions of the rat prelimbic medial prefrontal cortex affect cocaine- and MK-801-, but not morphine- and amphetamine-induced reward and psychomotor activation as measured with the place preference conditioning paradigm. *Behav Brain Res* 1998;97:115–27. [PubMed: 9867237]
42. Zavala AR, Weber SM, Rice HJ, Alleweireldt AT, Neisewander JL. Role of the prelimbic subregion of the medial prefrontal cortex in acquisition, extinction, and reinstatement of cocaine-conditioned place preference. *Brain Res* 2003;990:157–64. [PubMed: 14568340]
43. Boyce-Rustay JM, Cunningham CL. The role of NMDA receptor binding sites in ethanol place conditioning. *Behav Neurosci* 2004;118:822–34. [PubMed: 15301608]
44. Rassnick S, Pulvirenti L, Koob GF. Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. *Psychopharmacology* 1992;109:92–8. [PubMed: 1365677]
45. Spanagel R, Heilig M. Addiction and its brain science. *Addiction* 2005;100:1813–22. [PubMed: 16367982]

46. Sudakov SK, Rusakova IV, Trigub MM, Shakhmatov VY, Kozel' AI, Smith JE. Changed morphine sensitivity of morphine-dependent rats after laser exposure of the cerebral prefrontal cortex. *Bull Exp Biol Med* 2006;141:226–9. [PubMed: 16984103]
47. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat Neurosci* 2003;6:743–9. [PubMed: 12778052]
48. Cornish JL, Kalivas PW. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. *J Addict Dis* 2001;20:43–54. [PubMed: 11681592]
49. Cornish JL, Duffy P, Kalivas PW. A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. *Neuroscience* 1999;93:1359–67. [PubMed: 10501460]
50. Di Ciano P, Everitt BJ. Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. *Neuropsychopharmacology* 2001;25:341–60. [PubMed: 11522463]
51. Di Pietro NC, Black YD, Kantak KM. Context-dependent prefrontal cortex regulation of cocaine self-administration and reinstatement behaviors in rats. *Eur J Neurosci* 2006;24:3285–98. [PubMed: 17156389]
52. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. *J Neurosci* 2003;23:3531–7. [PubMed: 12716962]
53. McFarland K, Davidge SB, Lapish CC, Kalivas PW. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. *J Neurosci* 2004;24:1551–60. [PubMed: 14973230]
54. Backstrom P, Hyttia P. Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG. *Eur J Pharmacol* 2005;528:110–8. [PubMed: 16324694]
55. Backstrom P, Hyttia P. Ionotropic glutamate receptor antagonists modulate cue-induced reinstatement of ethanol-seeking behavior. *Alcohol Clin Exp Res* 2004;28:558–65. [PubMed: 15100606]
56. Backstrom P, Bachteler D, Koch S, Hyttia P, Spanagel R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. *Neuropsychopharmacology* 2004;29:921–8. [PubMed: 14735132]
57. Szumlinski KK, Frys KA, Kalivas PW. Dissociable roles for the dorsal and median raphe in the facilitatory effect of 5-HT1A receptor stimulation upon cocaine-induced locomotion and sensitization. *Neuropsychopharmacology* 2004;29:1675–87. [PubMed: 15127081]
58. Reid MS, Berger SP. Evidence for sensitization of cocaine-induced nucleus accumbens glutamate release. *NeuroReport* 1996;7:1325–9. [PubMed: 8817559]
59. Ito K, Abekawa T, Koyama T. Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine. *Psychopharmacology* 2006;187:293–302. [PubMed: 16850286]
60. Nash JF, Yamamoto BK. Effect of D-amphetamine on the extracellular concentrations of glutamate and dopamine in iprindole-treated rats. *Brain Res* 1993;627:1–8. [PubMed: 7904885]
61. Xue CJ, Ng JP, Li Y, Wolf ME. Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate and serine levels in rat ventral tegmental area and nucleus accumbens. *J Neurochem* 1996;67:352–63. [PubMed: 8667013]
62. Reid MS, Hsu K, Berger SP. Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: studies on the involvement of dopamine. *Synapse* 1997;27:95–105. [PubMed: 9266771]
63. Kalivas PW, Duffy P. Dopamine regulation of extracellular glutamate in the nucleus accumbens. *Brain Res* 1997;761:173–7. [PubMed: 9247082]
64. Moghaddam B, Bolinao ML. Biphasic effect of ethanol on extracellular accumulation of glutamate in the hippocampus and the nucleus accumbens. *Neurosci Lett* 1994;178:99–102. [PubMed: 7816349]
65. Saellstroem Baum S, Huebner A, Krimphove M, Morgenstern R, Badawy AA, Spies CD. Nicotine stimulation on extracellular glutamate levels in the nucleus accumbens of ethanol-withdrawn rats in vivo. *Alcohol Clin Exp Res* 2006;30:1414–21. [PubMed: 16899045]

66. Lallemand F, Ward RJ, Dravolina O, De Witte P. Nicotine-induced changes of glutamate and arginine in naive and chronically alcoholized rats: an in vivo microdialysis study. *Brain Res* 2006;1111:48–60. [PubMed: 16884696]
67. Liu Q, Li Z, Ding JH, Liu SY, Wu J, Hu G. Iptakalim inhibits nicotine-induced enhancement of extracellular dopamine and glutamate levels in the nucleus accumbens of rats. *Brain Res* 2006;1085:138–43. [PubMed: 16647046]
68. Kashkin VA, De Witte P. Nicotine increases microdialysate brain amino acid concentrations and induces conditioned place preference. *Eur Neuropsychopharmacol* 2005;15:625–32. [PubMed: 15916885]
69. Hao Y, Yang JY, Guo M, Wu CF, Wu MF. Morphine decreases extracellular levels of glutamate in the anterior cingulate cortex: an in vivo microdialysis study in freely moving rats. *Brain Res* 2005;1040:191–6. [PubMed: 15804441]
70. Jacobs EH, Wardeh G, Smit AB, Schoffelmeer AN. Morphine causes a delayed increase in glutamate receptor functioning in the nucleus accumbens core. *Eur J Pharmacol* 2005;511:27–30. [PubMed: 15777776]
71. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. *Alcohol Clin Exp Res* 2002;26:1779–93. [PubMed: 12500101]
72. Littleton J. Acamprosate in alcohol dependence: how does it work? *Addiction* 1995;90:1179–88. [PubMed: 7580816]
73. Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. *Clin Ther* 2005;27:695–714. [PubMed: 16117977]
74. Mason BJ. Acamprosate in the treatment of alcohol dependence. *Expert Opin Pharmacother* 2005;6:2103–15. [PubMed: 16197362]
75. Basu D, Jhirwal OP, Mattoo SK. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India. *Am J Addict* 2005;14:381–95. [PubMed: 16188718]
76. Rawson RA, McCann MJ, Hasson AJ, Ling W. Addiction pharmacotherapy 2000: new options, new challenges. *J Psychoactive Drugs* 2000;32:371–8. [PubMed: 11210198]
77. Park WK, Bari AA, Jey AR, Anderson SM, Spealman RD, Rowlett JK, Pierce RC. Cocaine administered into the medial prefrontal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens. *J Neurosci* 2002;22:2916–25. [PubMed: 11923456]
78. Backstrom P, Hyttia P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. *Psychopharmacology*. 2007Epub ahead of print
79. Pulvirenti L, Maldonado-Lopez R, Koob GF. NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. *Brain Res* 1992;594:327–30. [PubMed: 1360323]
80. Rodriguez-Borrero E, Bernardo Colon A, Burgos-Martir MA, Alvarez Carillo JE, del Campo YE, Abella-Ramirez C, et al. NMDA antagonist AP-5 increase environmentally induced cocaine-conditioned locomotion within the nucleus accumbens. *Pharmacol Biochem Behav* 2006;85:178–84. [PubMed: 16963113]
81. Cozzoli D, Goulding S, Szumlinski KK. Accumbens mGluR5 blockade reduces excessive alcohol consumption in mice. *Alcohol Clin Exp Ther*. 2007in press
82. Stromberg MF, Volpicelli JR, O'Brien CP, Mackler SA. The NMDA receptor partial agonist, 1-aminocyclopropanecarboxylic acid (ACPC), reduces ethanol consumption in the rat. *Pharmacol Biochem Behav* 1999;64:585–90. [PubMed: 10548275]
83. Cador M, Bjijou Y, Cailhol S, Stinus L. D-amphetamine-induced behavioral sensitization: implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation. *Neuroscience* 1999;94:705–21. [PubMed: 10579562]
84. Jolly DC, Kim JH, Vezina P. Activation of metabotropic glutamate receptors in the rat ventral tegmental area is necessary for induction of behavioral sensitization to amphetamine. *Soc Neurosci Abstr* 1997;23:1091.

85. Attarian S, Amalric M. Microinfusion of the metabotropic glutamate receptor agonist 1S, 3R-1-aminocyclopentane-1,3-dicarboxylic acid into the nucleus accumbens induces dopamine-dependent locomotor activation in the rat. *Eur J Neurosci* 1997;9:809–16. [PubMed: 9153588]
86. Kim JH, Vezina P. Metabotropic glutamate receptors in the rat nucleus accumbens contribute to amphetamine-induced locomotion. *J Pharmacol Exp Ther* 1998;284:317–22. [PubMed: 9435194]
87. Pulvirenti L, Swerdlow NR, Koob GF. Microinjection of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats. *Neurosci Lett* 1989;103:213–8. [PubMed: 2771183]
88. Willins DL, Wallace LJ, Miller DD, Uretsky NJ. α -Amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonists in the nucleus accumbens and ventral pallidum decrease the hypermotility response to psychostimulant drugs. *J Pharmacol Exp Ther* 1992;260:1145–51. [PubMed: 1372049]
89. Karler R, Bedingfield JB, Thai DK, Calder LD. The role of the frontal cortex in the mouse in behavioral sensitization to amphetamine. *Brain Res* 1997;757:228–35. [PubMed: 9200751]
90. Ma YY, Chu NN, Guo CY, Han JS, Cui CL. NR2B-containing NMDA receptor is required for morphine-but not stress-induced reinstatement. *Exp Neurol* 2007;203:309–19. [PubMed: 17014848]
91. Popik P, Kolasiewicz W. Mesolimbic NMDA receptors are implicated in the expression of conditioned morphine reward. *Naunyn Schmiedebergs Arch Pharmacol* 1999;359:288–94. [PubMed: 10344527]
92. Pulvirenti L, Swerdlow NR, Koob GF. Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. *Pharmacol Biochem Behav* 1991;40:841–5. [PubMed: 1687766]
93. Liechti ME, Markou A. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. *Eur J Pharmacol* 2007;554:164–74. [PubMed: 17113075]
94. Beshpalov AY, Dravolina OA, Sukhanov I, Zakharova E, Blokhina E, Zvartau E, et al. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. *Neuropharmacology* 2005;49:167–78. [PubMed: 16023685]
95. Paterson NE, Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. *Psychopharmacology* 2005;179:255–61. [PubMed: 15619120]
96. Tessari M, Pilla M, Andreoli M, Hutcheson DM, Heidbreder CA. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. *Eur J Pharmacol* 2004;499:121–33. [PubMed: 15363959]
97. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. *Psychopharmacology* 2003;167:257–64. [PubMed: 12682710]
98. Papp M, Gruca P, Willner P. Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. *Neuropsychopharmacology* 2002;27:727–43. [PubMed: 12431848]
99. Blokhina EA, Kashkin VA, Zvartau EE, Danysz W, Beshpalov AY. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. *Eur Neuropsychopharmacol* 2005;15:219–25. [PubMed: 15695068]
100. Glick SD, Maisonneuve IM, Dickinson HA, Kitchen BA. Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. *Eur J Pharmacol* 2001;422:87–90. [PubMed: 11430918]
101. McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. *Synapse* 2003;47:240–2. [PubMed: 12494407]
102. Brakeman PR, Lanahan AA, O'Brien R, Roche K, Barnes CA, Haganir RL, et al. Homer: a protein that selectively binds metabotropic glutamate receptors. *Nature* 1997;386:284–88. [PubMed: 9069287]
103. Foa L, Jensen K, Rajan I, Bronson K, Gasparini R, Worley PF, et al. Homer expression in the *Xenopus* tadpole nervous system. *J Comp Neurol* 2005;487:42–53. [PubMed: 15861458]

104. Kato A, Ozawa F, Saitoh Y, Fukazawa Y, Sugiyama H, Inokuchi K. Novel members of the Vesl/Homer family of PDZ proteins that bind metabotropic glutamate receptors. *J Biol Chem* 1998;273:23969–75. [PubMed: 9727012]
105. Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. *Neuron* 1998;21:707–16. [PubMed: 9808458]
106. Shiraishi Y, Mizutani A, Yuasa S, Mikoshiba K, Furuichi T. Differential expression of Homer family proteins in the developing mouse brain. *J Comp Neurol* 2004;473:582–99. [PubMed: 15116392]
107. Soloviev MM, Ciruela F, Chan WY, McIlhinney RA. Mouse brain and muscle tissues constitutively express high levels of Homer proteins. *Eur J Biochem* 2000;267:634–39. [PubMed: 10651798]
108. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. A complex program of striatal gene expression induced by dopaminergic stimulation. *J Neurosci* 1998;18:5301–10. [PubMed: 9651213]
109. Saito H, Kimura M, Inanobe A, Ohe T, Kurachi Y. An N-terminal sequence specific for a novel Homer1 isoform controls trafficking of group I metabotropic glutamate receptor in mammalian cells. *Biochem Biophys Res Commun* 2002;296:523–529. [PubMed: 12176012]
110. Bottai D, Guzowski JF, Schwarz MK, Kang SH, Xiao B, Lanahan A, et al. Synaptic activity-induced conversion of intronic to exonic sequence in Homer 1 immediate early gene expression. *J Neurosci* 2002;22:167–75. [PubMed: 11756499]
111. Klugmann M, Symes CW, Leichtle CB, Klaussner BK, Dunning J, Fong D, et al. AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. *Mol Cell Neurosci* 2005;28:347–60. [PubMed: 15691715]
112. Girault JA, Valjent E, Caboche J, Herve D. ERK2: a logical AND gate critical for drug-induced plasticity? *Curr Opin Pharmacol* 2007;7:77–85. [PubMed: 17085074]
113. Hope BT. Cocaine and the AP-1 transcription factor complex. *Ann N Y Acad Sci* 1998;844:1–6. [PubMed: 9668659]
114. Lu L, Koya E, Zhai H, Hope BT, Shaham Y. Role of ERK in cocaine addiction. *Trends Neurosci* 2006;29:695–703. [PubMed: 17084911]
115. McClung CA. The molecular mechanisms of morphine addiction. *Rev Neurosci* 2006;17:393–402. [PubMed: 17139840]
116. Nestler EJ. Molecular mechanisms of drug addiction. *Neuropharmacology* 2004;47 (Suppl 1):24–32. [PubMed: 15464123]
117. Nestler EJ. Is there a common molecular pathway for addiction? *Nat Neurosci* 2005;8:1445–9. [PubMed: 16251986]
118. Pandey SC. The gene transcription factor cyclic AMP-responsive element binding protein: role in positive and negative affective states of alcohol addiction. *Pharmacol Ther* 2004;104:47–58. [PubMed: 15500908]
119. Beneken J, Tu JC, Xiao B, Nuriya M, Yuan JP, Worley PF, et al. Structure of the Homer EVH1 domain-peptide complex reveals a new twist in polyproline recognition. *Neuron* 2000;26:143–54. [PubMed: 10798399]
120. Gertler FB, Niebuhr K, Reinhard M, Wehland J, Soriano P. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. *Cell* 1996;87:227–39. [PubMed: 8861907]
121. Reinhard M, Jarchau T, Walter U. Actin-based motility: stop and go with Ena/VASP proteins. *Trends Biochem Sci* 2001;26:243–9. [PubMed: 11295557]
122. Kim E, Sheng M. PDZ domain proteins of synapses. *Nat Rev Neurosci* 2004;5:771–81. [PubMed: 15378037]
123. Carpenter-Hyland EP, Chandler LJ. Adaptive plasticity of NMDA receptors and dendritic spines: implications for enhanced vulnerability of the adolescent brain to alcohol addiction. *Pharmacol Biochem Behav* 2007;86:200–8. [PubMed: 17291572]
124. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. *Nat Neurosci* 2001;4:873–4. [PubMed: 11528416]

125. Izzo E, Martin-Fardon R, Koob GF, Weiss F, Sanna PP. Neural plasticity and addiction: PI3-kinase and cocaine behavioral sensitization. *Nat Neurosci* 2002;5:1263–4. [PubMed: 12436114]
126. Hoffman PL. NMDA receptors in alcoholism. *Int Rev Neurobiol* 2003;56:35–82. [PubMed: 14696310]
127. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. *Ann N Y Acad Sci* 2003;1003:176–84. [PubMed: 14684445]
128. Lee B, Platt DM, Rowlett JK, Adewale AS, Spealman RD. Attenuation of behavioral effects of cocaine by the Metabotropic Glutamate Receptor 5 Antagonist 2-Methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. *J Pharmacol Exp Ther* 2005;312:1232–40. [PubMed: 15550570]
129. Toda S, Shen HW, Peters J, Cagle S, Kalivas PW. Cocaine increases actin cycling: effects in the reinstatement model of drug seeking. *J Neurosci* 2006;26:1579–87. [PubMed: 16452681]
130. Zhang X, Mi J, Wetsel WC, Davidson C, Xiong X, Chen Q, et al. PI3 kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity. *Biochem Biophys Res Commun* 2006;340:1144–50. [PubMed: 16414349]
131. Ango F, Robbe D, Tu JC, Xiao B, Worley PF, Pin JP, et al. Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons. *Mol Cell Neurosci* 2002;20:323–9. [PubMed: 12093163]
132. Shiraishi Y, Mizutani A, Mikoshiba K, Furuichi T. Coincidence in dendritic clustering and synaptic targeting of homer proteins and NMDA receptor complex proteins NR2B and PSD95 during development of cultured hippocampal neurons. *Mol Cell Neurosci* 2003;22:188–201. [PubMed: 12676529]
133. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, et al. Homer binds a novel proline-rich motif and links group I metabotropic glutamate receptors with IP3 receptors. *Neuron* 1998;21:717–26. [PubMed: 9808459]
134. Roche KW, Tu JC, Petralia RS, Xiao B, Wenthold RJ, Worley PF. Homer 1b regulates the trafficking of group I metabotropic glutamate receptors. *J Biol Chem* 1999;274:25953–7. [PubMed: 10464340]
135. Ango F, Pin JP, Tu JC, Xiao B, Worley PF, Bockaert J, et al. Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer1 proteins and neuronal excitation. *J Neurosci* 2000;20:8710–6. [PubMed: 11102477]
136. Kammermeier PJ, Xiao B, Tu JC, Worley PF, Ikeda SR. Homer proteins regulate coupling of group I metabotropic glutamate receptors to N-type calcium and M-type potassium channels. *J Neurosci* 2000;20:7238–45. [PubMed: 11007880]
137. Ango F, Prezeau L, Muller T, Tu JC, Xiao B, Worley PF, et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. *Nature* 2001;411:962–5. [PubMed: 11418862]
138. Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, et al. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. *Neuron* 1999;23:569–82. [PubMed: 10433268]
139. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. *Neuron* 1999;23:583–92. [PubMed: 10433269]
140. Sala C, Roussignol G, Meldolesi J, Fagni L. Key role of the postsynaptic density scaffold proteins Shank and Homer in the functional architecture of Ca²⁺ homeostasis at dendritic spines in hippocampal neurons. *J Neurosci* 2005;25:4587–92. [PubMed: 15872106]
141. Hwang JI, Kim HS, Lee JR, Kim E, Ryu SH, Suh PG. The interaction of phospholipase C-beta3 with Shank2 regulates mGluR-mediated calcium signal. *J Biol Chem* 2005;280:12467–73. [PubMed: 15632121]
142. Nakamura M, Sato K, Fukaya M, Araishi K, Aiba A, Kano M, et al. Signaling complex formation of phospholipase Cbeta4 with metabotropic glutamate receptor type 1alpha and 1,4,5-trisphosphate receptor at the perisynapse and endoplasmic reticulum in the mouse brain. *Eur J Neurosci* 2004;20:2929–44. [PubMed: 15579147]

143. Yuan JP, Kiselyov K, Shin DM, Chen J, Shcheynikov N, Kang SH, et al. Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors. *Cell* 2003;114:777–89. [PubMed: 14505576]
144. Shin DM, Dehoff M, Luo X, Kang SH, Tu J, Nayak SK, et al. Homer 2 tunes G protein-coupled receptors stimulus intensity by regulating RGS proteins and PLCbeta GAP activities. *J Cell Biol* 2003;162:293–303. [PubMed: 12860966]
145. Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. *Neuron* 2001;31:115–30. [PubMed: 11498055]
146. Shiraishi Y, Mizutani A, Bito H, Fujisawa K, Narumiya S, Mikoshiba K, et al. Cupidin, an isoform of Homer/Vesl, interacts with the actin cytoskeleton and activated rho family small GTPases and is expressed in developing mouse cerebellar granule cells. *J Neurosci* 1999;19:8389–400. [PubMed: 10493740]
147. Usui S, Konno D, Hori K, Maruoka H, Okabe S, Fujikado T, et al. Synaptic targeting of PSD-Zip45 (Homer 1c) and its involvement in the synaptic accumulation of F-actin. *J Biol Chem* 2003;278:10619–28. [PubMed: 12524440]
148. Ajima R, Kajiya K, Inoue T, Tani M, Shiraishi-Yamaguchi Y, Maeda M, et al. HOMER2 binds MYO18B and enhances its activity to suppress anchorage independent growth. *Biochem Biophys Res Commun* 2007;356:851–6. [PubMed: 17386922]
149. Kuriu T, Inoue A, Bito H, Sobue K, Okabe S. Differential control of postsynaptic density scaffolds via actin-dependent and -independent mechanisms. *J Neurosci* 2006;26:7693–706. [PubMed: 16855097]
150. Inoue Y, Honkura N, Kato A, Ogawa S, Udo H, Inokuchi K, et al. Activity-inducible protein Homer1a/Vesl-1S promotes redistribution of postsynaptic protein Homer1c/Vesl-1L in cultured rat hippocampal neurons. *Neurosci Lett* 2004;354:143–7. [PubMed: 14698459]
151. Shiraishi Y, Mizutani A, Mikoshiba K, Furuichi T. Coincidence in dendritic clustering and synaptic targeting of homer proteins and NMDA receptor complex proteins NR2B and PSD95 during development of cultured hippocampal neurons. *Mol Cell Neurosci* 2003;22:188–201. [PubMed: 12676529]
142. Rong R, Ahn JY, Huang H, Nagata E, Kalman D, Kapp JA, et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. *Nat Neurosci* 2003;6:1153–61. [PubMed: 14528310]
143. Hayashi MK, Ames HM, Hayashi Y. Tetrameric hub structure of postsynaptic scaffolding protein homer. *J Neurosci* 2006;26:8492–501. [PubMed: 16914674]
144. Sun J, Tadokoro S, Imanaka T, Murakami SD, Nakamura M, Kashiwada K, et al. Isolation of PSD-Zip45, a novel Homer/vesl family protein containing leucine zipper motifs, from rat brain. *FEBS Lett* 1998;437:304–8. [PubMed: 9824313]
145. de Bartolomeis A, Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. *Psychopharmacol Bull* 2003;37:51–83. [PubMed: 14608240]
146. Fagni L, Worley PF, Ango F. Homer as both a scaffold and transduction molecule. *Sci STKE* 2002 :RE8.
147. Xiao B, Tu JC, Worley PF. Homer: a link between neural activity and glutamate receptor function. *Curr Opin Neurobiol* 2000;10:370–4. [PubMed: 10851183]
148. Szumlinski KK, Kalivas PW, Worley PF. Homer proteins: implications for neuropsychiatric disorders. *Curr Opin Neurobiol* 2006;16:251–7. [PubMed: 16704932]
149. Duncan RS, Hwang SY, Koulen P. Effects of Vesl/Homer proteins on intracellular signaling. *Exp Biol Med* 2005;230:527–35.
150. Kato A, Ozawa F, Saitoh Y, Hirai K, Inokuchi K. vesl, a gene encoding VASP/Ena family related protein, is upregulated during seizure, long-term potentiation and synaptogenesis. *FEBS Lett* 1997;412:183–9. [PubMed: 9257717]
151. McFarland K, Kalivas PW. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. *J Neurosci* 2001;21:8655–63. [PubMed: 11606653]

152. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. *Nat Neurosci* 2005;8:1442–4. [PubMed: 16251985]
153. Koob GF. Alcoholism: allostasis and beyond. *Alcohol Clin Exp Res* 2003;27:232–43. [PubMed: 12605072]
154. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. *Nat Neurosci* 2005;8:1481–9. [PubMed: 16251991]
155. Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. *Neurosci Biobehav Rev* 2002;26:321–52. [PubMed: 12034134]
156. See RE. Neural substrates of cocaine-cue associations that trigger relapse. *Eur J Pharmacol* 2005;526:140–6. [PubMed: 16253228]
157. Ary AW, Aguilar VR, Szumlinski KK, Kippin TE. Prenatal stress alters limbo-corticostratial Homer protein expression. *Synapse*. 2007in press
158. Kaja S, Yang SH, Wei J, Fujitani K, Liu R, Brun-Zinkernagel AM, et al. Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Ves1-IL/Homer 1c immunoreactive synaptic connections. *Invest Ophthalmol Vis Sci* 2003;44:3155–62. [PubMed: 12824266]
159. Fujiyama K, Kajii Y, Hiraoka S, Nishikawa T. Differential regulation by stimulants of neocortical expression of *mrt1*, *arc*, and *homer1a* mRNA in the rats treated with repeated methamphetamine. *Synapse* 2003;49:143–9. [PubMed: 12774298]
160. Ghasemzadeh MB, Acker CJ, Permenter LK, Lake R, Kalivas PW. The regulation of Homer1 gene expression after acute and repeated cocaine administration in the mesocorticolimbic circuit. *Soc Neurosci Abstr* 2006;831.3.
161. Nichols CD, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. *Neuropsychopharmacology* 2002;26:634–42. [PubMed: 11927188]
162. Nichols CD, Garcia EE, Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. *Mol Brain Res* 2003;111:182–8. [PubMed: 12654518]
163. Kane JK, Hwang Y, Konu O, Loughlin SE, Leslie FM, Li MD. Regulation of Homer and group I metabotropic glutamate receptors by nicotine. *Eur J Neurosci* 2005;21:1145–54. [PubMed: 15813924]
164. Cochran SM, Fujimura M, Morris BJ, Pratt JA. Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. *Synapse* 2002;46:206–14. [PubMed: 12325047]
165. Ammon S, Mayer P, Riechert U, Tischmeyer H, Holtt V. Microarray analysis of genes expressed in the frontal cortex of rats chronically treated with morphine and after naloxone precipitated withdrawal. *Mol Brain Res* 2003;112:113–25. [PubMed: 12670709]
166. Zhang GC, Mao LM, Liu XY, Parekar NK, Arora A, Yang L, et al. In vivo regulation of Homer1a expression in the striatum by cocaine. *Mol Pharmacol* 2007;71:1148–58. [PubMed: 17234898]
167. Ary AW, Szumlinski KK, Ben-Shahar O. Brief versus extended access to cocaine differentially alters the expression of Group 1 mGluRs and Homer proteins in the prefrontal cortex of rats. *Soc Neurosci Abstr* 2006:294.2.
168. Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK. Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties. *Drug Alcohol Depend* 2006;85:142–56. [PubMed: 16697125]
169. Swanson CJ, Baker DA, Carson D, Worley PF, Kalivas PW. Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer. *J Neurosci* 2001;21:9043–52. [PubMed: 11698615]
170. Szumlinski KK. Homer1: A link between cortical glutamate dysfunction and cocaine addiction? *Soc Neurosci Abstr* 2006:699.6.
171. Sala C, Futai K, Yamamoto K, Worley PF, Hayashi Y, Sheng M. Inhibition of dendritic spine morphogenesis and synaptic transmission by activity-inducible protein Homer1a. *J Neurosci* 2003;23:6327–37. [PubMed: 12867517]

172. Szumlinski KK, Lominac KD, Kleschen MJ, Oleson EB, Dehoff MH, Schwarz MK, et al. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. *Genes Brain Behav* 2005;4:273–88. [PubMed: 16011574]
173. Lominac KD, Oleson EB, Pava M, Klugmann M, Schwarz MK, Seeburg PH, et al. Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. *J Neurosci* 2005;25:11586–94. [PubMed: 16354916]
174. Baker DA, Shen H, Kalivas PW. Cystine/glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration. *Amino Acids* 2002;23:161–2. [PubMed: 12373531]
175. Melendez RI, Vuthiganon J, Kalivas PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. *J Pharmacol Exp Ther* 2005;314:139–47. [PubMed: 15769865]
176. Williams M, Reyes C, Szumlinski KK. *Homer1* deletion does not alter mesolimbic glutamate receptor expression. *Soc Neurosci Abstr.* 2007in press
177. Brenman JE, Christopherson KS, Craven SE, McGee AW, Brecht DS. Cloning and characterization of postsynaptic density 93, a nitric oxide synthase interacting protein. *J Neurosci* 1996;16:7407–15. [PubMed: 8922396]
178. Burette A, Zabel U, Weinberg RJ, Schmidt HH, Valtchanoff JG. Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus. *J Neurosci* 2002;22:8961–70. [PubMed: 12388603]
179. Christopherson KS, Hillier BJ, Lim WA, Brecht DS. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. *J Biol Chem* 1999;274:27467–73. [PubMed: 10488080]
180. Brecht DS, Snyder SH. Transient nitric oxide synthase neurons in embryonic cerebral cortical plate, sensory ganglia, and olfactory epithelium. *Neuron* 1994;13:301–13. [PubMed: 7520252]
181. Moncada S. The 1991 Ulf von Euler Lecture. The L-arginine: nitric oxide pathway. *Acta Physiol Scand* 1992;145:201–27. [PubMed: 1381545]
182. Brecht DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. *Annu Rev Biochem* 1994;63:175–95. [PubMed: 7526779]
183. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 1991;43:109–42. [PubMed: 1852778]
184. Robinson TE, Kolb B. Structural plasticity associated with exposure to drugs of abuse. *Neuropharmacology* 2004;47 (Suppl 1):33–46. [PubMed: 15464124]
185. Stanwood GD, Levitt P. Drug exposure early in life: functional repercussions of changing neuropharmacology during sensitive periods of brain development. *Curr Opin Pharmacol* 2004;4:65–71. [PubMed: 15018841]
186. Garner CC, Nash J, Huganir RL. PDZ domains in synapse assembly and signalling. *Trends Cell Biol* 2000;10:274–80. [PubMed: 10856930]
187. Kennedy MB. Signal-processing machines at the postsynaptic density. *Science* 2000;290:750–4. [PubMed: 11052931]
188. Okabe S. Molecular anatomy of the postsynaptic density. *Mol Cell Neurosci* 2007;34:503–518. [PubMed: 17321751]
189. Scannevin RH, Huganir RL. Postsynaptic organization and regulation of excitatory synapses. *Nat Rev Neurosci* 2000;1:133–141. [PubMed: 11252776]
190. Fagni L, Ango F, Perroy J, Bockaert J. Identification and functional roles of metabotropic glutamate receptor-interacting proteins. *Semin Cell Dev Biol* 2004;15:289–98. [PubMed: 15125892]
191. Ehlers MD. Molecular morphogens for dendritic spines. *Trends Neurosci* 2002;25:64–7. [PubMed: 11814549]
192. Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. *Nature* 1999;399:66–70. [PubMed: 10331391]
193. Korkotian E, Segal M. Bidirectional regulation of dendritic spine dimensions by glutamate receptors. *NeuroReport* 1999;10:2875–2877. [PubMed: 10511456]

194. Kaeck S, Brinkhaus H, Matus A. Volatile anesthetics block actin-based motility in dendritic spines. *Proc Natl Acad Sci USA* 1999;96:10433–10437. [PubMed: 10468626]
195. Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. *Science* 1999;283:1923–1927. [PubMed: 10082466]
196. Toni N, Buchs PA, Nikonenko I, Bron CR, Muller D. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. *Nature* 1999;402:421–425. [PubMed: 10586883]
197. Kaeck S, Parmar H, Roelandse M, Bornmann C, Matus A. Cytoskeletal microdifferentiation: a mechanism for organizing morphological plasticity in dendrites. *Proc Natl Acad Sci U S A* 2001;98:7086–92. [PubMed: 11416192]
198. Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. *J Neurosci* 1997;17:8491–7. [PubMed: 9334421]
199. Robinson TE, Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. *Eur J Neurosci* 1999;11:1598–1604. [PubMed: 10215912]
200. Ferrario CR, Gorny G, Crombag HS, Li Y, Kolb B, Robinson TE. Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. *Biol Psychiatry* 2005;58:751–9. [PubMed: 16098484]
201. Heijtz RD, Kolb B, Forssberg H. Can a therapeutic dose of amphetamine during pre-adolescence modify the pattern of synaptic organization in the brain? *Eur J Neurosci* 2003;18:3394–3399. [PubMed: 14686913]
202. Kolb B, Gorny G, Li Y, Samaha AN, Robinson TE. Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens. *Proc Natl Acad Sci USA* 2003;100:10523–10528. [PubMed: 12939407]
203. Li Y, Kolb B, Robinson TE. The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen. *Neuropsychopharmacology* 2003;238:1082–1085. [PubMed: 12700699]
204. Crombag HS, Gorny G, Li Y, Kolb B, Robinson TE. Opposite effects of amphetamine self-administration experience on dendritic spines in the medial and orbital prefrontal cortex. *Cereb Cortex* 2005;15:341–8. [PubMed: 15269111]
205. Robinson TE, Gorny G, Mitton E, Kolb B. Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. *Synapse* 2001;39:257–266. [PubMed: 11169774]
206. Li Y, Acerbo MJ, Robinson TE. The induction of behavioural sensitization is associated with cocaine-induced structural plasticity in the core (but not shell) of the nucleus accumbens. *Eur J Neurosci* 2004;20:1647–54. [PubMed: 15355332]
207. Norrholm SD, Bibb JA, Nestler EJ, Ouimet CC, Taylor JR, Greengard P. Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5. *Neuroscience* 2003;116:19–22. [PubMed: 12535933]
208. Brown RW, Kolb B. Nicotine sensitization increases dendritic length and spine density in the nucleus accumbens and cingulate cortex. *Brain Res* 2001;899:94–100. [PubMed: 11311869]
209. Gonzalez CL, Gharbawie OA, Whishaw IQ, Kolb B. Nicotine stimulates dendritic arborization in motor cortex and improves concurrent motor skill but impairs subsequent motor learning. *Synapse* 2005;55:183–91. [PubMed: 15635590]
210. Robinson TE, Kolb B. Morphine alters the structure of neurons in the nucleus accumbens and neocortex of rats. *Synapse* 1999;33:160–162. [PubMed: 10400894]
211. Robinson TE, Gorny G, Savage VR, Kolb B. Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats. *Synapse* 2002;46:271–279. [PubMed: 12373743]
212. Lescaudron L, Jaffard R, Verna A. Modifications in number and morphology of dendritic spines resulting from chronic ethanol consumption and withdrawal: a Golgi study in the mouse anterior and posterior hippocampus. *Exp Neurol* 1989;106:156–163. [PubMed: 2478383]

213. Tarello-Acuna L, Olvera-Cortes E, Gonzalez-Burgos I. Prenatal and postnatal exposure to ethanol induces changes in the shape of the dendritic spines from hippocampal CA1 pyramidal neurons of the rat. *Neurosci Lett* 2000;286:13–16. [PubMed: 10822141]
214. Carpenter-Hyland EP, Chandler LJ. Homeostatic plasticity during alcohol exposure promotes enlargement of dendritic spines. *Eur J Neurosci* 2006;24:3496–506. [PubMed: 17229098]
215. Zhou FC, Anthony B, Dunn KW, Lindquist WB, Xu ZC, Deng P. Chronic alcohol drinking alters neuronal dendritic spines in the brain reward center nucleus accumbens. *Brain Res* 2007;1134:148–61. [PubMed: 17198693]
216. Carpenter-Hyland EP, Woodward JJ, Chandler LJ. Chronic ethanol induces synaptic but not extrasynaptic targeting of NMDA receptors. *J Neurosci* 2004;24:7859–68. [PubMed: 15356198]
217. Chandler LJ. Ethanol and brain plasticity: receptors and molecular networks of the postsynaptic density as targets of ethanol. *Pharmacol Ther* 2003;99:311–26. [PubMed: 12951163]
218. Okabe S, Urushido T, Konno D, Okado H, Sobue K. Rapid redistribution of the postsynaptic density protein PSD-Zip45 (Homer 1c) and its differential regulation by NMDA receptors and calcium channels. *J Neurosci* 2001;21:9561–71. [PubMed: 11739567]
219. Kato A, Fukuda T, Fukazawa Y, Isojima Y, Fujitani K, Inokuchi K, et al. Phorbol esters promote postsynaptic accumulation of Vesl-1S/Homer-1a protein. *Eur J Neurosci* 2001;13:1292–302. [PubMed: 11298789]
220. Ebihara T, Kawabata I, Usui S, Sobue K, Okabe S. Synchronized formation and remodeling of postsynaptic densities: long-term visualization of hippocampal neurons expressing postsynaptic density proteins tagged with green fluorescent protein. *J Neurosci* 2003;23:2170–81. [PubMed: 12657676]
221. Foa L, Rajan I, Haas K, Wu GY, Brakeman P, Worley P, et al. The scaffold protein, Homer1b/c, regulates axon pathfinding in the central nervous system in vivo. *Nat Neurosci* 2001;4:499–506. [PubMed: 11319558]
222. Murmu MS, Salomon S, Biala Y, Weinstock M, Braun K, Bock J. Changes of spine density and dendritic complexity in the prefrontal cortex in offspring of mothers exposed to stress during pregnancy. *Eur J Neurosci* 2006;24:1477–87. [PubMed: 16965544]
223. Rebec GV, Sun W. Neuronal substrates of relapse to cocaine-seeking behavior: role of prefrontal cortex. *J Exp Anal Behav* 2005;84:653–66. [PubMed: 16596984]
224. Carlezon WA Jr, Nestler EJ. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? *Trends Neurosci* 2002;25:610–5. [PubMed: 12446127]
225. Kalivas PW. Recent understanding in the mechanisms of addiction. *Curr Psychiatry Rep* 2004;6:347–51. [PubMed: 15355757]
226. Self DW, Choi KH. Extinction-induced neuroplasticity attenuates stress-induced cocaine seeking: a state-dependent learning hypothesis. *Stress* 2004;7:145–55. [PubMed: 15764012]
227. Wang JQ, Liu X, Zhang G, Parelkar NK, Arora A, Haines M, et al. Phosphorylation of glutamate receptors: a potential mechanism for the regulation of receptor function and psychostimulant action. *J Neurosci Res* 2006;84:1621–9. [PubMed: 16983660]
228. Koe BK. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. *J Pharmacol Exp Ther* 1976;199:649–61. [PubMed: 994022]
229. Ary AW, Szumlinski KK. Regionally selective regulation of Homer proteins by withdrawal from repeated cocaine. *Soc Neurosci Abstr.* 2007in press
230. Ahmed SH, Koob GF. Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. *Psychopharmacology* 2005;180:473–90. [PubMed: 15731896]
231. Ben-Shahar O, Ahmed SH, Koob GF, Ettenberg A. The transition from controlled to compulsive drug use is associated with a loss of sensitization. *Brain Res* 2004;995:46–54. [PubMed: 14644470]
232. Ben-Shahar O, Keeley P, Cook M, Brake W, Joyce M, Nyffeler M, et al. Changes in levels of D1, D2, or NMDA receptors during withdrawal from brief or extended daily access to IV cocaine. *Brain Res* 2007;1131:220–8. [PubMed: 17161392]
233. Ahmed SH, Cador M. Dissociation of psychomotor sensitization from compulsive cocaine consumption. *Neuropsychopharmacology* 2006;31:563–71. [PubMed: 16034440]

234. Ben-Shahar O, Moscarello JM, Jacob B, Roarty MP, Ettenberg A. Prolonged daily exposure to i.v. cocaine results in tolerance to its stimulant effects. *Pharmacol Biochem Behav* 2005;82:411–6. [PubMed: 16253318]
235. Ben-Shahar O, Moscarello JM, Ettenberg A. One hour, but not six hours, of daily access to self-administered cocaine results in elevated levels of the dopamine transporter. *Brain Res* 2006;1095:148–53. [PubMed: 16712814]
236. Mantsch JR, Yuferov V, Mathieu-Kia AM, Ho A, Kreek MJ. Effects of extended access to high versus low cocaine doses on self-administration, cocaine-induced reinstatement and brain mRNA levels in rats. *Psychopharmacology* 2004;175:26–36. [PubMed: 15042275]
237. Obara I, Ary AW, Szumlinski KK, Ben-Shahar O. Differential alterations in mesocorticolimbic Homer and glutamate receptor protein expression by one and six hours of daily access to self-administered cocaine. *Soc Neurosci Abstr.* 2007in press
238. Ghasemzadeh MB, Permenter LK, Lake R, Worley PF, Kalivas PW. Homer1 proteins and AMPA receptors modulate cocaine-induced behavioural plasticity. *Eur J Neurosci* 2003;18:1645–51. [PubMed: 14511343]
239. Dietrich JB, Arpin-Bott MP, Kao D, Dirrig-Grosch S, Aunis D, Zwiller J. Cocaine induces the expression of homer 1b/c, homer 3a/b, and hsp 27 proteins in rat cerebellum. *Synapse* 2007;61:587–594. [PubMed: 17455232]
240. Tappe A, Kuner R. Regulation of motor performance and striatal function by synaptic scaffolding proteins of the Homer1 family. *Proc Natl Acad Sci U S A* 2006;103:774–9. [PubMed: 16407107]
241. Dahl JP, Kampman KM, Oslin DW, Weller AE, Lohoff FW, Ferraro TN, et al. Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population. *Psychiatr Genet* 2005;15:277–83. [PubMed: 16314758]
242. Minami K, Gereau RW 4th, Minami M, Heinemann SF, Harris RA. Effects of ethanol and anesthetics on type 1 and 5 metabotropic glutamate receptors expressed in *Xenopus* oocytes. *Mol Pharmacol* 1998;53:148–156. [PubMed: 9443943]
243. Lovinger DM. Interactions between ethanol and agents that act on the NMDA-type glutamate receptor. *Alcohol Clin Exp Res* 1996;20 (Suppl):187A–191A.
244. Woodward JJ. Ethanol and NMDA receptor signaling. *Crit Rev Neurobiol* 2000;14:69–89. [PubMed: 11253956]
245. Dahchour A, Quertemont E, De Witte P. Acute ethanol increases taurine but neither glutamate nor GABA in the nucleus accumbens of male rats: a microdialysis study. *Alcohol Alcohol* 1994;29:485–7. [PubMed: 7811331]
246. Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. *Psychiatry Res* 1998;82:107–14. [PubMed: 9754453]
247. Dahchour A, De Witte P. Taurine blocks the glutamate increase in the nucleus accumbens microdialysate of ethanol-dependent rats. *Pharmacol Biochem Behav* 2000;65:345–50. [PubMed: 10672989]
248. Melendez RI, Hicks MP, Cagle SS, Kalivas PW. Ethanol exposure decreases glutamate uptake in the nucleus accumbens. *Alcohol Clin Exp Res* 2005;29:326–33. [PubMed: 15770106]
249. Dahchour A, De Witte P. Excitatory and inhibitory amino acid changes during repeated episodes of ethanol withdrawal: an in vivo microdialysis study. *Eur J Pharmacol* 2003;459:171–8. [PubMed: 12524143]
250. Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. *Alcohol Clin Exp Res* 2003;27:465–70. [PubMed: 12658112]
251. Szumlinski KK, Diab ME, Friedman R, Henze LM, Lominac KD, Bowers MS. Accumbens neurochemical adaptations produced by binge-like alcohol consumption. *Psychopharmacology* 2007;190:415–431. [PubMed: 17225170]
252. Hendricson AW, Maldve RE, Salinas AG, Theile JW, Zhang TA, Diaz LM, Morrisett RA. Aberrant synaptic activation of NMDA receptors underlies ethanol withdrawal hyperexcitability. *J Pharmacol Exp Ther.* 2007Epub ahead of press

253. Smothers CT, Mrotek JJ, Lovinger DM. Chronic ethanol exposure leads to a selective enhancement of N-methyl-D-aspartate receptor function in cultured hippocampal neurons. *J Pharmacol Exp Ther* 1997;283:1214–22. [PubMed: 9399996]
254. Chen F, Jarrott B, Lawrence AJ. Up-regulation of cortical AMPA receptor binding in the fawn-hooded rat following ethanol withdrawal. *Eur J Pharmacol* 1999;384:139–46. [PubMed: 10611433]
255. Szumlinski KK. Up, Up and Away! Facilitation of alcohol-induced neural plasticity by Homer over-expression. *Alcohol Clin Exp Ther* 2006;30 (Suppl):60A.
256. Szumlinski KK, Friedman J, Rahn A, Cozzoli D, Ary AW. Excessive alcohol consumption sensitizes glutamate transmission: Link to Homer proteins and kinase activation. *Neuropsychopharmacology* 2006;31:S140.
257. Olive MF, McGeehan AJ, Kinder JR, McMahon T, Hodge CW, Janak PH, et al. The mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine decreases ethanol consumption via a protein kinase C epsilon-dependent mechanism. *Mol Pharmacol* 2005;67:349–355. [PubMed: 15548766]
258. Gutala R, Wang J, Kadapakkam S, Hwang Y, Ticku M, Li MD. Microarray analysis of ethanol-treated cortical neurons reveals disruption of genes related to the ubiquitin-proteasome pathway and protein synthesis. *Alcohol Clin Exp Res* 2004;28:1779–88. [PubMed: 15608593]
259. Sokolov BP, Jiang L, Trivedi NS, Aston C. Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. *J Neurosci Res* 2003;72:756–67. [PubMed: 12774316]
260. Urizar NL, Yang Z, Edenberg HJ, Davis RL. Drosophila homer is required in a small set of neurons including the ellipsoid body for normal ethanol sensitivity and tolerance. *J Neurosci* 2007;27:4541–4551. [PubMed: 17460067]
261. Diagana TT, Thomas U, Prokopenko SN, Xiao B, Worley PF, Thomas JB. Mutation of Drosophila homer disrupts control of locomotor activity and behavioral plasticity. *J Neurosci* 2002;22:428–36. [PubMed: 11784787]
262. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. *J Pharmacol Exp Ther* 1995;274:90–6. [PubMed: 7616454]
263. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: A review. *Prog Neurobiol* 2005;75:406–33. [PubMed: 15955613]
264. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. Rapid and reversible effects of methamphetamine on dopamine transporters. *J Pharmacol Ex Ther* 1997;282:834–38.
265. Kita T, Wagner GC, Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. *J Pharmacol Sci* 2003;92:178–95. [PubMed: 12890883]
266. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. *Schizophr Bull* 1992;18:115–22. [PubMed: 1553491]
267. Imam SZ, el-Yazal J, Newport GD, Itzhak Y, Cadet JL, Slikker W Jr, et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. *Ann N Y Acad Sci* 2001;939:366–80. [PubMed: 11462792]
268. Sonsalla PK. The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines. *Drug Alcohol Depend* 1995;37:101–5. [PubMed: 7758399]
269. Robinson TE, Castaneda E, Whishaw IQ. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. *Can J Psychol* 1990;44:253–75. [PubMed: 2116937]
270. Seiden LS, Commins DL, Vosmer G, Axt K, Marek G. Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. *Ann N Y Acad Sci* 1988;537:161–72. [PubMed: 3059922]
271. Shoblock JR, Sullivan EB, Maisonneuve IM, Glick SD. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. *Psychopharmacology* 2003;165:359–69. [PubMed: 12491026]
272. Zhang Y, Loonam TM, Noailles PA, Angulo JA. Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat

- brain during acute, chronic, and early withdrawal conditions. *Ann N Y Acad Sci* 2001;937:93–120. [PubMed: 11458542]
273. Kim JS, Kornhuber HH, Brand U, Menge HG. Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia. *Neurosci Lett* 1981;24:93–96. [PubMed: 6115345]
 274. Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. *Brain Res* 1992;581:237–243. [PubMed: 1356579]
 275. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. *Synapse* 1994;17:203–209. [PubMed: 7974204]
 276. Abekawa T, Ohmori T, Koyama T. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. *Brain Res* 1994;643:276–281. [PubMed: 7518327]
 277. Stephans SE, Yamamoto BY. Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex. *Brain Res* 1995;700:99–106. [PubMed: 8624733]
 278. Lu W, Chen H, Xue CJ, Wolf ME. Repeated amphetamine administration alters the expression of mRNA for AMPA receptor subunits in rat nucleus accumbens and prefrontal cortex. *Synapse* 1997;26:269–80. [PubMed: 9183816]
 279. Lu W, Wolf ME. Repeated amphetamine administration alters AMPA receptor subunit expression in rat nucleus accumbens and medial prefrontal cortex. *Synapse* 1999;32:119–31. [PubMed: 10231131]
 280. Lu W, Monteggia LM, Wolf ME. Withdrawal from repeated amphetamine administration reduces NMDAR1 expression in the rat substantia nigra, nucleus accumbens and medial prefrontal cortex. *Eur J Neurosci* 1999;11:3167–77. [PubMed: 10510180]
 281. Eisch AJ, O'Dell SJ, Marshall JF. Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine. *Synapse* 1996;22:217–25. [PubMed: 9132989]
 282. Kashiwabara K, Sato M, Otsuki S. Reduction of 3H-kainic acid binding in rat cerebral cortex by chronic methamphetamine administration. *Biol Psychiat* 1984;19:1173–1181. [PubMed: 6093902]
 283. Ghasemzadeh MB, Nelson LC, Lu XY, Kalivas PW. Neuroadaptations in ionotropic and metabotropic glutamate receptor mRNA produced by cocaine treatment. *J Neurochem* 1999;72:157–65. [PubMed: 9886066]
 284. Boudreau AC, Wolf ME. Behavioral sensitization to cocaine is associated with increased AMPA receptor surface expression in the nucleus accumbens. *J Neurosci* 2005;25:9144–51. [PubMed: 16207873]
 285. Churchill L, Swanson CJ, Urbina M, Kalivas PW. Repeated cocaine alters glutamate receptor subunit levels in the nucleus accumbens and ventral tegmental area of rats that develop behavioral sensitization. *J Neurochem* 1999;72:2397–403. [PubMed: 10349849]
 286. Lominac KD, Szumlinski KK. Up-regulation of Homer and glutamate receptor protein expression in the nucleus accumbens by psychomimetic and anti-psychotic agents. *Soc Neurosci Abstr* 2006;32:589.1.
 287. Koob GF. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. *Addiction* 2006;101 (Suppl 1):23–30. [PubMed: 16930158]
 288. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. *Eur J Pharmacol* 2005;526:36–50. [PubMed: 16289451]
 289. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. *Nat Neurosci* 2005;8:1450–7. [PubMed: 16251987]
 290. Goeders NE. The impact of stress on addiction. *Eur Neuropsychopharmacol* 2003;13:435–41. [PubMed: 14636959]
 291. Lu L, Shepard JD, Hall FS, Shaham Y. Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review. *Neurosci Biobehav Rev* 2003;27:457–91. [PubMed: 14505687]

292. Yang J, Li W, Liu X, Li Z, Li H, Yang G, et al. Enriched environment treatment counteracts enhanced addictive and depressive-like behavior induced by prenatal chronic stress. *Brain Res* 2006;1125:132–7. [PubMed: 17109826]
293. Ludman EJ, McBride CM, Nelson JC, Curry SJ, Grothaus LC, Lando HA, et al. Stress, depressive symptoms, and smoking cessation among pregnant women. *Health Psychol* 2000;19:21–7. [PubMed: 10711584]
294. Deminiere JM, Piazza PV, Guegan G, Abrous N, Maccari S, Le Moal M, et al. Increased locomotor response to novelty and propensity to intravenous amphetamine self-administration in adult offspring of stressed mothers. *Brain Res* 1992;586:135–9. [PubMed: 1511342]
295. Kippin TE, Szumlinski KK, Kapasova Z, Rezner B, See RE. Prenatal stress enhances the psychomotor stimulant, motivational, and neurochemical effects of cocaine. *Neuropsychopharmacology*. 2007in press
296. Brown SM, Henning S, Wellman CL. Mild, short-term stress alters dendritic morphology in rat medial prefrontal cortex. *Cereb Cortex* 2005;15:1714–1722. [PubMed: 15703248]
297. Cook SC, Wellman CL. Chronic stress alters dendritic morphology in rat medial prefrontal cortex. *J Neurobiol* 2004;60:236–248. [PubMed: 15266654]
298. Kolb B, Gorny G, Soderpalm AH, Robinson TE. Environmental complexity has different effects on the structure of neurons in the prefrontal cortex versus the parietal cortex or nucleus accumbens. *Synapse* 2003;48:149–53. [PubMed: 12645040]
299. Venton BJ, Robinson TE, Kennedy RT. Transient changes in nucleus accumbens amino acid concentrations correlate with individual responsivity to the predator fox odor 2,5-dihydro-2,4,5-trimethylthiazoline. *J Neurochem* 2006;96:236–46. [PubMed: 16300631]
300. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. *J Neurochem* 1993;60:1650–7. [PubMed: 8097232]
301. Saulskaya N, Marsden CA. Extracellular glutamate in the nucleus accumbens during a conditioned emotional response in the rat. *Brain Res* 1995;698:114–20. [PubMed: 8581469]
302. Vazdarjanova A, McNaughton BL, Barnes CA, Worley PF, Guzowski JF. Experience-dependent coincident expression of the effector immediate-early genes arc and Homer 1a in hippocampal and neocortical neuronal networks. *J Neurosci* 2002;22:10067–71. [PubMed: 12451105]
303. Igaz LM, Bekinschtein P, Izquierdo I, Medina JH. One-trial aversive learning induces late changes in hippocampal CaMKIIalpha, Homer 1a, Syntaxin 1a and ERK2 protein levels. *Brain Res Mol Brain Res* 2004;132:1–12. [PubMed: 15548423]
304. Koenig JI, Elmer GI, Shepard PD, Lee PR, Mayo C, Joy B, et al. Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. *Behav Brain Res* 2005;156:251–61. [PubMed: 15582111]
305. Weinstock M. Alterations induced by gestational stress in brain morphology and behaviour of the offspring. *Prog Neurobiol* 2001;65:427–51. [PubMed: 11689280]
306. Henry C, Guegant G, Cador M, Arnault E, Arsaut J, Le Moal M, et al. Prenatal stress in rats facilitates amphetamine-induced sensitization and induces long-lasting changes in dopamine receptors in the nucleus accumbens. *Brain Res* 1995;685:179–86. [PubMed: 7583244]
307. Jaubert PJ, Golub MS, Lo YY, Germann SL, Dehoff MH, Worley PF, et al. Complex, multimodal behavioral profile of the Homer1 knockout mouse. *Genes Brain Behav* 2007;6:141–54. [PubMed: 16734773]
308. Alterman AI, Erdlen DL, Laporte DL, Erdlen FR. Effects of illicit drug use in an inpatient psychiatric setting. *Addict Behav* 1982;73:231–242. [PubMed: 7180617]
309. Barbee JG, Clark PD, Crapanzano MS, Heintz GC, Kehoe CE. Alcohol and substance abuse among schizophrenic patients present to an emergency psychiatric service. *J Nerv Mental Disease* 1989;177:400–407.
310. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. *J Nerv Mental Disease* 1989;177:408–414.
311. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. *Acta Psychiatr Scand* 1992;85:48–55. [PubMed: 1546548]

312. Mueser, KT.; Bennett, M.; Kushner, MG. Epidemiology of substance use disorders among persons with chronic mental illnesses. In: Lehman, AF.; Dixon, LB., editors. Double jeopardy: chronic mental illness and substance use disorders vol. 3. 9. Longhorne Pennsylvania: Harwood Academic Publishers; 1995. p. 25
313. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. *J Nerv Mental Disease* 1987;175:641–652.
314. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. *J Am Med Assoc* 1990;264:2511–2518.
315. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. *Schizophr Res* 1999;35:93–100.
316. Hays P, Aidroos N. Alcoholism followed by schizophrenia. *Acta Psychiat Scand* 1985;742:187–189.
317. Negrete JC, Knapp WP. The effects of cannabis use on the clinical condition of schizophrenics. *NIDA Res Monogr* 1986;67:321–327. [PubMed: 3092086]
318. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR, Burns BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. *Am J Psychiat* 1998;155:226–231. [PubMed: 9464202]
319. Tracy JI, Josiassen RC, Bellack AS. Neuropsychology of dual diagnosis: understanding the combined effects of schizophrenia and substance use disorders. *Clin Psychol Rev* 1995;15:67–97.
320. Cohen LJ, Test MA, Brown RJ. Suicide and schizophrenia: data from a prospective community treatment study. *Am J Psychiat* 1990;147:602–607. [PubMed: 2327487]
321. Landmark J, Cernovsky ZZ, Merskey H. Correlates of suicide attempts and ideation in schizophrenia. *Brit J Psychiat* 1987;151:18–20.
322. Carpenter WTJ, Heinrichs DW, Alphas LD. Treatment of negative symptoms. *Schizophr Bull* 1985;11:440–452. [PubMed: 2863871]
323. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. *Arch Gen Psychiat* 1994;51:273–279. [PubMed: 8161287]
324. Sokolski KN, Cummings JL, Abrams BI, DeMet EM, Katz LS, Costa JF. Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. *J Clin Psychiat* 1994;55:380–387.
325. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, Davis JM, Lewis DA. Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. *Am J Psychiat* 1995;152:856–861. [PubMed: 7755114]
326. Norton N, Williams HJ, Williams NM, Spurlock G, Zammit S, Jones G, et al. Mutation screening of the Homer gene family and association analysis in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* 2003;120:18–21. [PubMed: 12815733]
327. Fourgeaud L, Mato S, Bouchet D, Hemar A, Worley PF, Manzoni OJ. A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens. *J Neurosci* 2004;24:6939–45. [PubMed: 15295029]

Figure 1.
Illustration of the putative interactions between (A) constitutively expressed (CC) Homer proteins and (B) IEG Homer proteins with their EVH1-bound partners within the postsynaptic density of dendritic spines.

Figure 2.

Homer protein levels are differentially regulated in the cell body and terminal regions of the corticoaccumbens glutamate pathway by cocaine. Immunoblotting for total Homer protein expression was conducted on NAC and PFC tissue from C57BL/6J mice at 3 weeks withdrawal from repeated cocaine (7 X 30 mg/kg) or saline administration. Bottom panels: Anti-Homer1b/c and anti-Homer2a/b primary antibodies recognized bands at 47 kDa [e.g., 39,144,169,295]. Left: Cocaine-treated mice showed an approximately 50% reduction in Homer1b/c ($t_{20}=2.34$, $p=0.03$) and Homer2a/b ($t_{20}=2.32$, $p=0.03$) within the NAC. Right: Cocaine-treated mice did not differ from saline controls regarding Homer1b/c expression ($p=0.95$), but exhibited an approximately 30% increase in Homer2a/b ($t_{20}=2.45$, $p=0.02$). * $p<0.05$ for saline versus cocaine.

Table 1
Summary of findings regarding the regulation of IEG Homer expression in vivo by drugs of abuse. Rx=treatment

Homer isoform	Region	Treatment	Effect vs. Control	Reference
Acute Drug Treatment				
<i>Homer1a</i>	<i>Striatum</i>	Cocaine injection	mRNA ↑ at 2 hrs	102
	NAC	Cocaine injection	protein ↑ at 2 hrs	166
	Neocortex or PFC	Cocaine injection	mRNA ↑ at 2 hrs	160
	VTA	Cocaine injection	mRNA ↑ at 1–2 hrs	159,160
	Neocortex	Cocaine injection	mRNA ↑ at 2 hrs	160
<i>Ania-3</i>	PFC, auditory and granular retrosplenial cortices	Methamphetamine injection	mRNA ↑ at 1 hr	159
	PFC	phencyclidine (PCP) injection	mRNA ↑ at 2 & 24 hrs	164
	PFC	lysergic acid diethylamide (LSD) injection	mRNA ↑ at 1.5 hrs	161
Repeated Drug Treatment				
<i>Homer1a</i>	PFC, NAC, and VTA	LSD injection	mRNA ↑ at 1.5–3 hrs	161,162
	Neocortex	Cocaine injections	no change	160
		Methamphetamine injections + methamphetamine or cocaine challenge injection	mRNA ↑ at 1 hr	159
<i>Ania-3</i>	NAC	Nicotine injections	mRNA ↓ after 3 days of Rx no change after 7 or 14 days of Rx	163
	frontal cortex	Morphine injections + withdrawal with or without a naloxone injection	mRNA ↑ at 4 hrs	165

Summary of findings regarding the regulation of CC-Homer protein or mRNA expression in vivo by drugs of abuse. Rx=treatment

Table 2

Homer isoform	Region	Treatment	Effect	Reference
Acute Drug Treatment				
Homer1b/c	NAC	Cocaine injection	Protein ↑ at 1 hr	327
	NAC	Alcohol injection	no change in protein at 24 hr	255
	Cerebellum	Cocaine injection	Protein ↑ at 15 hr	239
	NAC	Alcohol injection	Protein ↑ at 24 hr	255
	Cerebellum	Cocaine injection	Protein ↑ at 15 hr	239
Repeated Drug Treatment	NAC	Cocaine injections	No change in protein at 24 hr	169,228
	NAC	1-hr cocaine self-administration	Protein ↓ at 3 weeks	Fig. 1
	NAC	6-hr cocaine self-administration	Protein ↓ at 24 hr, but not at 2 weeks	237
	NAC	Methamphetamine injections	Protein ↓ at 24 hr, but not at 2 weeks	237
	NAC	Alcohol injections	No change at 24 hr	286
	NAC	Continuous alcohol consumption	No change at 24 hr	255
	NAC	Binge alcohol consumption	No change at 2 days, 2 weeks and 2 months	39
	NAC	Nicotine injections	No change at 24 hr	256
	NAC	Nicotine injections	mRNA ↑ after 14, but not 3 or 7 days Rx	163
	NAC	Nicotine injections	Protein ↑ after 3, but not 7 or 14 days Rx; no mRNA change with any Rx	163
	NAC	Nicotine injections	Protein ↑ after 3, but not 7 or 14 days of Rx; no mRNA change with any Rx	163
	NAC	Cocaine injections	No protein change at 24 hr or 3 weeks	169,228
	NAC	1-hr cocaine self-administration	No change in protein at 24 hr or 2 weeks	Fig. 1
	NAC	6-hr cocaine self-administration	Protein ↑ at 24 hr, but not at 2 weeks	167
	NAC	Cocaine injections	Protein ↑ at 15 hr	167,237
	NAC	Cocaine injections	Protein ↓ at 3 weeks	239
	NAC	1-hr cocaine self-administration	No change at 24 hr	228
	NAC	6-hr cocaine self-administration	Protein ↓ at 2 weeks	Fig. 1
	NAC	Methamphetamine injections	Protein ↓ at 2 weeks	237
	NAC	Alcohol injections	No change at 24 hr	286
	NAC	Continuous alcohol consumption	Protein ↑ at 3 weeks	255
	NAC	Binge alcohol consumption	Protein ↑ at 2 days, 2 weeks and 2 months	39
	NAC	Nicotine injections	Protein ↑ at 24 hr	256
	NAC	Nicotine injections	No change in mRNA or protein	163
	NAC	Nicotine injections	mRNA ↑ after 3, but not 7 or 14 days Rx; no protein change with any Rx	163
	NAC	Nicotine injections	Protein ↑ after 3, but not 7 or 14 days of Rx; no mRNA change with any Rx	163
	NAC	Cocaine injections	Protein ↑ at 3 weeks	228
	NAC	1-hr cocaine self-administration	No change in protein at 24 hr or 2 weeks	Fig. 1
	NAC	6-hr cocaine self-administration	No change in protein at 24 hr or 2 weeks	167
	NAC	Cocaine injections	Protein ↑ at 15 hrs	239

Table 3
Comparison of the corticolimbic glutamate alterations produced by Homer1 and Homer2 deletion. ND=not yet determined

Region	Measure	Homer1	Homer2	Reference
NAC	Basal glutamate content	WT>KO	WT>KO	34,38,172,173
	Cocaine-induced glutamate release	WT<KO	WT<KO	34,172,173
	Alcohol-induced glutamate release	ND	WT>KO	38
	Group1 mGluR agonist-induced glutamate release	ND	WT>KO	34
	Cystine-induced glutamate release	ND	WT>KO	34
	Total mGluR1a protein	WT=KO	WT>KO	34,176
	Plasma membrane mGluR1a protein	ND	WT=KO	38
	Total mGluR5 protein	WT=KO	WT=KO	34,176
	Plasma membrane mGluR5 protein	ND	WT=KO	38
	Total NR2a	WT=KO	WT=KO	34,176
	Plasma membrane NR2a protein	ND	WT>KO	38
	Total NR2a	WT=KO	WT=KO	34,176
	Plasma membrane NR2a protein	ND	WT>KO	38
	Total Xc expression	ND	WT>KO	34
PFC	Basal glutamate content	WT<KO	WT=KO	34,172,173
	Cocaine-induced glutamate release	WT>KO	WT=KO	172,173
	High potassium-stimulated release	WT>KO	ND	170
	Total mGluR1a, mGluR5, NR2a, NR2b protein	WT=KO	ND	176